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Summary 
 
Throughout history disease entities have been described which match the 
description of diseases now known to be caused by hantaviruses; however these 
viruses were first identified as the aetiologic agent in 1976, the first species named 
Hantaan virus after the river near which its natural host, the rodent species 
Apodemus agrarius, was captured. Since then numerous species in the Hantavirus 
genus, family Bunyaviridae, have been found, with today more than 30 species 
worldwide being known.  
Hantaviruses are hosted by rodents from the Muridae and Cricetidae families and by 
shrews (insectivores) in the Soricidae family. There are two types of hantavirus 
disease, Haemorrhagic fever with renal syndrome (HFRS) in the Old World and 
Hantavirus cardiopulmonary syndrome (HCPS) in the New World. The first two 
African hantaviruses were identified in 2006 in Guinea, West Africa; Sangassou virus 
(SANGV) in a rodent, the African wood mouse (Hylomyscus simus), and Tanganya 
virus (TGNV) in Therese’s shrew (Crocidura theresae). 
In this study, rodents and shrews were trapped at localities in the Western Cape and 
Northern Cape provinces of South Africa, and in the southern regions of Namibia. 
RNA was extracted from their lungs and screened for hantavirus sequences by RT-
PCR, using degenerate primers designed to detect all members of the Hantavirus 
genus.   
In addition, an in-house IgG ELISA assay was set up, based on recombinant N 
antigen from Dobrava virus, DOB-rN, and Puumala virus, PUU-rN. The assay was 
used to screen patient sera collected in an anonymous convenience serological 
survey using residual serum samples left over from routine testing at NHLS 
laboratories in the Western Cape for hantavirus-specific antibodies.  
RNA from 576 animal specimens was screened by RT-PCR; no hantavirus genome 
was detected in any of the specimens. Sera from 161 patients were screened for 
hantavirus antibodies; 11.18% of the sera were reactive to DOB-rN, 4.97% against 
PUU-rN and 2.48% against both antigens. 
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Though no virus was detected in the animals screened, this does not necessarily 
mean that there are no hantaviruses present in Southern Africa. A previous 
seroepidemiological survey conducted in South Africa reported on the presence of 
hantavirus specific antibodies by IFA in two species of rodents trapped in the 
Western Cape and Northern Cape Aethomys namquensis and Tatera leucogaster. 
Our was the second known study in South Africa conducted that determined and 
proved the presence of hantavirus specific antibodies in humans.  
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Opsomming 
 
Dwarsdeur die geskiedenis was daar beskrywings van siektes wat ooreenstem met 
die beskrywing van hantavirus simptome, maar die eerste etiologiese oorsaak van 
die siekte is eers in 1976 geïdentifiseer en Hantaan virus genoem, vernoem na die 
rivier waar naby die gasheer, Apodemus agrarius, gevang is. Van daar af het die 
soektog na nuwe hantavirusse intensief gevorder en vandag is daar meer as 30 
spesies wêreldwyd wat aan die Hantavirus genus, ’n lid van die Bunyaviridae familie, 
behoort.  
Knaagdiere van die Muridae en Cricetidae families, sowel as spitsmuise (insek-
vreters) in die Soricidae familie is gasheer vir hantavirusse. Twee tipes hantavirus 
siekte is bekend, hemorragische koors met nier sindroom (HFRS) in die Ou Wêreld 
en hantavirus kardiopulmonale sindroom in die Nuwe Wêreld. Die eerste twee Afrika 
hantavirusse is in 2006 in Guinee Wes-Afrika geïdentifiseer; Sangassou virus 
(SANGV) in ’n knaagdier, die Afrika hout muis (Hylomyscus simus) en Tanganya 
virus (TGNV) in Therese se spitsmuis (Crocidura theresae). 
In hierdie studie is knaagdiere en spitsmuise op verskeie plekke in die Wes- en 
Noord-Kaap provinsies, asook die Suide van Namibië, gevang. RNS is onttrek vanuit 
die longe en hantavirus volgordes is gesoek deur middel RT-PKR deur gebruik te 
maak van Pan-Hanta primers wat ontwerp is om alle lede van die Hantavirus genus 
op te spoor. ’n Self-ontwerpde IgG ELISA, gebasseer op rekombinante N antigeen 
van Dobrava virus, DOB-rN en Puumala virus, PUU rN, is opgestel en gebruik om 
pasiënt serum, verkry in ’n anonieme serologiese opname, te toets; oorblywende 
serum, na toetse uitgevoer is deur NHLS laboratoriums in die Wes-Kaap, is verkry 
en getoets vir hantavirus spesifieke teenliggaampies. 
RNS van 576 dier monsters is getoets deur middel van RT-PKR en geen hantavirus 
is in enige van die monsters geïdentifiseer nie. Serum van 161 pasiënte is getoets vir 
hantavirus teenliggaampies; 11.18% van die serum was reaktief teen DOB-rN, 
4.97% teen PUU-rN en 2.48% teen albei antigene. 
Alhoewel geen virus in die diere geïdentifiseer is nie, beteken dit nie noodwendig dat 
geen hantavirusse in Suidelike-Afrika voorkom nie. ‘n Vorige sero-epidemiologiese 
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opname wat in Suid-Afrika gedoen is het die teenwoordigheid van hantavirus 
spesifieke teenliggaampies in twee knaagdier spesies,  Aethomys namquensis en 
Tatera leucogaster gevang in die Wes-en Noord-Kaap, gevind. Ons studie is die 
tweede studie bekend in Suid-Afrika uitgevoer, wat die teenwoordigheid van 
hantavirus spesifieke teenliggaampies bevind en bewys het. 
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CHAPTER 1 
Introduction  
 
1.1 History of Hantaviruses 
There have been reports of diseases likely caused by hantavirus infections 
throughout history; haemorrhagic fever with renal syndrome-like disease was 
described in Chinese archives as early as 1000 years ago (Klein & Calisher, 2007). 
Nephropathia epidemica was described by Swedish scientists in 1934 and several 
thousands of allied and German troops during World War II were affected by field 
nephritis (Vapalahti et al, 2003; Clement et al, 2007).  “Songo fever” or epidemic 
haemorrhagic fever was first described in the 1930s as well; 12 600 cases of disease 
with fever occurred among Japanese troops during the invasion of northern China 
(Clement et al, 2007).  
 
The hantavirus disease came to the forefront during the Korean war (1950-53) when 
approximately 3200 cases were reported among the American soldiers (Hart & 
Bennett. 1999). The causative agent, the Hantaan virus (HTNV) and its host 
Apodemus agarius, was only identified in 1976 (Lee et al, 1978). In 1993 another 
hantaviral disease was reported in the United States of America, when an outbreak 
of a febrile lung disease with high mortality occurred in the Four Corners region. The 
causative agent was hitherto unknown member of the genus hantavirus (Enria et al, 
2001). Subsequent investigations in the area of the outbreak led to the identification 
of the reservoirs host, the rodent Peromyscus maniculatus (Johnson, 2001).  
Hantaviruses can be classified into Old World and New World hantaviruses based on 
geographic distribution and the type of disease they induce in human beings. 
Hantaviruses are transmitted to human beings from their natural reservoir hosts 
which are different species of rodents and shrews. Old World hantaviruses are 
harboured by members of the Arvicolinae and Murinae subfamilies in Europe, Asia 
and Africa, whereas the New World viruses are harboured by members of the 
Sigmondontinae and Neotominae subfamilies in North and South America (Clement 
et al, 2007; Ramanathan & Jonsson, 2008). Old World hantaviruses cause 
haemorrhagic fever with renal syndrome (HFRS), which includes Korean and 
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epidemic haemorrhagic fever and the clinically less severe nephropathia epidemica 
(NE). In the New World, hantavirus infection results in hantavirus cardiopulmonary 
syndrome (HCPS) (Vapalahti et al, 2003). As many as 150 000 cases of HFRS are 
reported worldwide, more than half of them in China. More than 21 known hantavirus 
species are associated with clinical illness, ranging from mild proteinuria to life-
threatening haemorrhagic fever and pulmonary oedema (Jonsson et al, 2010).  
 
Figure 1.1 Worldwide distribution of hantavirus diseases.  
Severe HFRS is Europe is caused by Dobrava virus infection and the milder form of HFRS, 
NE, is mainly as a result of Puumala virus infection. In Asia, Hantaan virus and Seoul virus 
infections result in HFRS (though Seoul virus infections have been reported elsewhere in the 
world due to the ubiquitous distribution of its host Rattus norvergicus). In the Americas 
hantavirus infection results in HCPS disease which mostly caused by Sin Nombre virus in 
North and Andes virus in South America [Source: Preiser, 2008]. 
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1.2 Hantaviruses in Africa 
The first studies providing evidence for the occurrence of hantavirus infections in 
Africa was performed by Gonzalez et al 1984 in Benin, Burkina Faso, Central African 
Republic and Gabon (Bi et al, 2008). Subsequent serological studies were performed 
in 1985 in Senegal (Saluzzo et al, 1985), in Nigeria (Tomori et al, 1986), Djibouti 
(Rodier et al, 1993) and Egypt (Botros et al, 2004). In all five studies human sera 
were tested for hantavirus-specific IgG antibodies. But only one case of HFRS has 
been reported from Africa, in 1987 in the Central African Republic.  
 
However, the first African hantavirus was only identified in 2006 in Guinea, West 
Africa. The Sangassou virus (SANGV) was isolated from the African woodmouse 
Hylomyscus simus (Klempa et al, 2006). A second hantavirus, the Tanganya virus 
(TGNV), was identified in a non-rodent insectivore host, Therese’s shrew (Crocidura 
theresae), also in Guinea (Klempa et al, 2007). The identification of these first 
hantaviruses in Africa suggests that there may be other hantaviruses in other parts 
of Africa, too. It is conceivable that these viruses may cause human infection and 
even disease, which may well have gone undetected so far as hantavirus-induced 
pathology may be confused with disease caused by other infectious aetiologies such 
as leptospirosis, rickettsiosis, other viral haemorrhagic fevers, plague, severe 
pneumonia, sepsis or may simply have remained unrecognized due to poor 
standards of health care.   
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1.3 Aims and Objectives 
This study was conducted in order to investigate the possible presence of 
hantaviruses in Southern African small animal reservoirs, i.e. different species of 
rodents and shrews, by molecular methods, and to characterise any viruses that 
might thus be identified. The aim of this project is further to use these findings to 
establish diagnostic assays for the identification of hantaviruses infection in human 
beings including patients. 
Objectives: 
• To determine the prevalence of hantaviruses in rodent and shrew reservoirs in 
Southern Africa 
• To identify and characterise novel hantaviruses by molecular and classical 
virological methods  
• To establish serological diagnostic assays for the identification of 
hantaviruses in human disease cases 
• To determine the prevalence of hantavirus antibodies in human beings from 
different parts of Southern Africa, with particular emphasis on rural areas 
• To determine the potential occurrence of hantavirus-induced pathology in 
human beings in Southern Africa 
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CHAPTER 2 
2 Literature Review 
2.1 Natural History of Hantaviruses 
The Hantavirus genus was formally defined in 1985 (Harper & Meyer, 1999) and 
currently comprises of more than 30 different species and is the only haemorrhagic 
fever virus with worldwide distribution including the temperate regions of the 
Northern hemisphere. Hantaviruses were placed in the Bunyaviridae family with four 
other genera; the Phlebovirus and later Nairovirus, Orthobunyavirus and the plant 
pathogenic Tospovirus genus which includes other human pathogenic viruses such 
as Rift Valley fever virus  and Crimean-Congo haemorrhagic fever (CCHF) virus 
(Hart & Bennett, 1999; Harper & Meyer, 1999; Weidmann et al, 2003).  
All other members of the Bunyaviridae family are arthropod-borne and are 
transmitted by vectors such as culicoid flies, mosquitoes, thrips and ticks (Lambert & 
Lanciotti, 2009), while hantaviruses are transmitted from rodents and insectivores 
(Weidmann et al, 2003; Lambert & Lanciotti, 2009), in which they have co-evolved 
for millions of years (St Jeor et al, 2005; Vaheri et al, 2008; Clement et al, 2007).  
The first hantavirus to be isolated was Thottapalayam virus (TPMV) from the Asian 
house shrew (Suncus Murinus) and was initially classified as an arbovirus, but 
subsequent investigations showed that the virus belongs in the Hantavirus genus by 
its ultrastructural features and its overall genetic similarities to well characterised 
rodent-borne hantaviruses (Clement et al, 2007; Song et al, 2007b) . The isolation of 
TPMV predates the isolation of the HTNV, the prototype virus of the genus by 14 
years (Song et al, 2007b).  
Hantaviruses are divided into 2 main groups based on geographical distribution; Old 
World in Europe and Asia and New World viruses in the Americas. But there is great 
divergence in each group and the viruses are further subdivided based on nucleotide 
and protein sequences (Plyusnin & Morzunov, 2001; Jonsson et al, 2010). According 
to the international committee on virus taxonomy (ICTV) 7% is the minimum protein 
divergence required for a virus to be considered a species (Lednicky et al, 2003). 
Maes et al (2009) suggested the following additions to the current criteria; for group 
demarcation the amino acid distance must be greater than 24% on the S segment 
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and greater than 32% on the M segment. In the case of species demarcation, an 
amino acid distance greater than 10% and 12% on the S segment and M segment 
respectively.  
 
 
Figure 2.1 Maximum-likelihood phylogenetic consensus trees.  
Trees generated based on partial  1048-nucleotide S- (left tree) and 347-nucleotide L-
genomic segments (right tree) of shrew-borne viruses; Jemez Springs virus (JMSV) and Ash 
River virus (ARRV ) Cao Bang virus (CBNV) , Tanganya virus (TGNV) from the Therese 
shrew (Crocidura theresae), and Thottapalayam virus (TPMV) as well as  representative 
Murinae rodent-borne hantaviruses;  Hantaan virus (HTNV), Sangassou virus (SANV) from 
the African wood mouse (Hylomiscus simus) , Dobrava virus (DOBV), and Seoul virus 
(SEOV). Arvicolinae rodent-borne hantaviruses, Tula virus (TULV), Prospect Hill virus (PHV) 
and Puumala virus (PUUV) and Sigmodontinae and Neotominae rodent-borne hantaviruses, 
including Andes virus (ANDV) and Sin Nombre virus (SNV) [Source: Arai et al, 2008]. 
 
 The figure above is phylogenetic tree constructed from partial L and S segments of 
some members in the Hantavirus genus. Tree shows that based on the S- segment, 
viruses are grouped according to reservoir host; Arvicolinae-borne viruses cluster 
together, the same can be concluded for Murinae-borne viruses. For the shrew 
viruses, 4 of the viruses hosted by members of the Crocidurinae subfamily cluster 
together and TPMV. L –segment analysis shows a similar picture for the Muridae 
borne viruses but TGNV does not cluster with CBNV, JMSV and ARRV as observed 
for the S –segment.  
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2.2 Hantavirus Morphology 
Hantaviruses are enveloped viruses with a negative sense, single-stranded RNA 
genome. Like all other members of the Bunyaviridae family, the hantavirus genome 
has three segments (Hart & Bennett, 1999; Vaheri et al, 2008). Hantaviruses have 
the simplest coding strategy in the family; all three segments only encode one 
protein in the virus complementary sense (McCaughey & Hart, 2000). The large (L), 
medium (M) and small (S): The large segment (~6500 nt) encodes the RNA-
dependent RNA polymerase, the medium segment (~3700 nt) encodes the two 
envelope glycoproteins: Gn and Gc and the small segment (~1800 nt) encodes the 
nucleocaspid N protein (Hart & Bennett, 1999; Vaheri et al, 2008).  
 
A molecular feature found to distinguish hantaviruses from other members of the 
Bunyaviridae family is the presence of conserved, complementary terminal 
panhandle nucleotide sequence (AUCAUCAUC) on the L, M and S segments (figure 
2.2) (McCaughey & Hart, 2000; Jonsson & Schmaljohn, 2001). It is this characteristic 
and the absence of cross-reactivity among other members of the family that are the 
basis for the proposal that led to the establishment of the Hantavirus genus in 1985 
(Jonsson & Schmaljohn, 2001). 
 
Figure 2.2The terminal panhandle sequences at the 5'- and 3'- ends of the S, M and L RNA 
segments. [Source: Kukkonen et al, 2005]. 
 
By electron microscopy, hantavirus virions are roughly spherical with a diameter that 
varies from 80 nm to 210 nm (McCaughey & Hart, 2000; Spiropoulou, 2001). A 
hantavirus virion consists of an internal nucleocapsid arranged in circular coils, it is 
surrounded by a ~5 nm bi-layered membrane. The surface glycoproteins, Gc and Gn 
appear as projections that are ~6 nm in length. The virion is composed of >50% 
protein, 20-30% lipid and 2-7% carbohydrate (McCaughey & Hart, 2000).  
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Figure 2.3 Illustration of hantavirus morphology [Source: Muranyi et al, 2005] 
 
2.3 Viral Replication and Transcription  
The main components of hantavirus replication are the RNA-dependent RNA 
polymerase (RdRp), the Nucleocapsid protein (N), and the viral genomic and 
antigenomic RNA templates (Jonsson & Schmaljohn, 2001). The RdRp is 
responsible for the synthesis of positive strand messenger RNA from the L, M, and S 
viral RNA segments; it mediates both transcription and replication (Jonsson & 
Schmaljohn, 2001). Sometime after transcription has been initiated, RdRp initiates 
virus replication by the synthesis of copy RNA (cRNA) by an unknown mechanism. 
The newly synthesised cRNA can act as template for the synthesis of viral RNA 
(vRNA). Two mechanisms have been suggested for the synthesis of vRNA: (1) the 
UTP initiated genome synthesis pathway or (2) the prime-and-realign mechanism. 
The vRNA can either serve as a template for mRNA during the early stages of 
infection or it can be packed into virions in the later stages of infection (St Jeor et al, 
2005). 
Hantavirus transcription and replication takes place in the cytoplasm of the target cell 
(St Jeor et al, 2005). Shortly after virion entry and uncoating, primary transcription is 
initiated by RdRp, soon after initial transcription viral replication is initiated by RdRp 
by an unknown mechanism (Jonsson & Schmaljohn, 2001).  
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Transcription occurs by the prime-and-realign mechanism (Figure 1.3). Process 
begins with the cleavage of a primer from the 5’end of the host mRNA, all the 
primers used in transcription must have a G at the 3’terminus (Kaukinen et al, 2005). 
This primer is then aligned a few nucleotides upstream from the 3’end of the viral 
template and elongated with a few nucleotides, and then realigned so that the G on 
the host-derived primer is at position −1 and the recently added nucleotides on the 
mRNA basepair with the viral template (Jonsson & Schmaljohn, 2001). Final 
elongation then occurs where the entire viral template is transcribed until the RdRp 
encounters the termination signal. RdRp is responsible for both transcription and 
replication. The exact mechanism for the switch from primary transcription to 
replication is not known however  the switch most likely occurs once the production 
of viral proteins such as the N protein (products of primary transcription and 
translation) reaches a threshold level (Jonsson & Schmaljohn, 2001; Kaukinen et al, 
2005).  
2.4 Entry Mechanism into Target Cells  
Virus replication mainly takes place in the macrophages and vascular endothelial 
cells especially in the lungs and kidneys (Muranyi et al, 2005). Pathogenic 
hantaviruses enter the host cells by attaching to αvβ3 integrins on the cell surface 
and susbsequent endocytosis (Gavrilovskaya et al, 1998; Muranyi et al, 2005).  
When hantaviruses infect both the natural reservoir host and humans they infect 
endothelial cells, macrophages, kidney glomerula and epithelial cells primarily (Jin et 
al, 2002). Early entry of the virus into the target cells involves virus attachment to the 
β3 integrin cell surface receptors. The exact mechanism by which hantaviruses 
attach to the cell surface is unknown however, the pathway by which the virus enters 
the target cell was determined in experiments using endocytosis inhibitors: the 
prototype virus of the Hantavirus genus, Hantaan virus (HTNV) was used (Mackow & 
Gavrilovskaya, 2001). Experimentation using the HTNV and endocytosis inhibitors 
by Jin et al concluded that hantaviruses are internalized in to the host cell by clathrin-
dependent receptor-mediated endocytosis by showing that inhibition of the clathrin-
dependent pathway resulted in the inhibition of infection (Jin et al, 2002).   
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2.5 Hantavirus Infection in Natural Reservoir Host  
A variety of small mammals serve as reservoir hosts for hantaviruses. Current 
evidence suggests those viruses and their hosts have co-evolved, resulting in 
specific hantaviruses being closely associated with a certain host species. The 
geographical range of the reservoir host species thus defines the geographic range 
of the hantavirus: Hantaan virus is carried by Apodemus agrarius coreae (field 
mouse) in Asia (Lee et al, 1978) (Figure 2.4). The range of Apodemus species 
includes most of Europe; the Balkans, western Russia, parts of Spain and France as 
well as south Scandinavia and extends into Asia China, Korea, Japan and Mongolia. 
Apodemus agrarius present in Asia and Europe harbours Hantaan and Dobrava 
virus (Muranyi et al, 2005). Puumala virus is carried by Myodes glareolus (bank 
voles) in Europe and its range is restricted to most of Western Europe and 
Scandinavia as well as the British Isles and Ireland (Muranyi et al, 2005).  
 
The Seoul virus is the only known hantavirus with a worldwide range because it’s 
hosts Rattus species are found worldwide (Mackow & Gavrilovskaya, 2001; Jonsson 
et al, 2010).  Sin Nombre and New York viruses are by Peromyscus species 
(Neotominae subfamily) and found exclusively in America (Clement et al, 2007).  
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Figure 2.4 Selected hantavirus reservoir hosts. 
Apodemus agrarius coreae is the host for Hantaan virus (HTNV), the prototype virus of the 
genus. Peromyscus maniculatus is the host of Sin Nombre virus (SNV) and Hylomyscus 
simus is the host for the first African hantavirus that has been identified, Sangassou virus 
(SANGV). [Sources: discoverlife.org, animalpicturesarchive.com & sflorg.com/sciencenews] 
 
Table 2.1 Selected hantavirus species, their main reservoir host and human disease 
that they cause. [Modified from Schönrich et al, 2008] 
 
 
 
Above: Apodemus agrarius coreae
Left: Peromyscus Maniculatus
Above: Hylomyscus simus
Order Family Subfamily Species Virus Human disease
Old World viruses Rodentia Muridae Murinae Apodemus agrarius Hantaan HFRS
A. flavicollis, A. agrarius Dobrava HFRS
Rattus rattus, Rattus norvegicus Seoul HFRS
Hylomyscus  (alleni) simus Sangassou
Arvicolinae Myodes glareolus Puumala NE
Microtus arvalis, M. agrestis Tula HFRS
Eulipotyphla/ Soricidae Crocidurinae Crocidura theresae Tanganya Unknown
Soricomorpha Suncus murinus Thottapalayam Unknown
Soricinae Sorex araneus Seewis Unknown
Anourosorex squamipes Cao Bang Unknown
New World viruses Rodentia Muridae Arvicolinae Microtus pennsylvanicus Prospect Hill HCPS
M. ochrogaster Isla vista HCPS
Neotominae Peromyscus maniculatus Sin Nombre HCPS
P. leucopus New York HCPS
Sigmodontinae Oligoryzomys longicautdatus Andes HCPS
other Oligoryzomys sp.
Oryzomys palutris Bayou HCPS
Eulipotyphla/ Soricidae Soricinae Sorex cinereus Ash River Unknown
Soricomorpha S. monticolus Jemez Springs Unknown
Blarina brevicauda Camp Ripley Unknown
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The distribution of hantavirus infections in a host species population is affected by 
behavioural patterns. Males are more frequently infected than females because they 
engage more frequently in aggressive behaviour which results in wounding and thus 
the transmission of infection. The incidence of infection also differs between juvenile 
and adult males. The incidence and severity of wounding is much higher in adult 
males and thus the incidence of hantavirus infection as well (Hinson et al, 2004). A 
study in bank voles found that adults with most wounds at the end of the breeding 
season (autumn) would be more likely to be infected than the non-wounded animals 
(Escutanaire et al, 2002). 
Longitudinal studies of Norway rats infected with Seoul virus and deer mice infected 
with Sin Nombre virus showed that in a population of rodents, age determines who is 
infected with the virus and wounding during fights is the primary means by which 
infection is acquired or transmitted (Botten et al, 2003; Hinson et al, 2004; 
Easterbrook & Klein, 2008). Susceptibility to viral infection differs between males and 
females. Males are more susceptible to infection because females mount a higher 
immune response than males. Observation of Norway rats infected with the Seoul 
virus, have shown that males shed the virus for longer periods of time and via more 
routes than the females. The viral load in the target organs is also much higher in the 
males (Klein et al, 2002; Hannah et al, 2008). Transmission among rodents also 
occurs by inhalation of aerosol of excrement and urine that contain infectious viral 
particles (Easterbrook & Klein, 2008).  
Rodents infected with persistent hantavirus infection are not put at any survival 
disadvantage. They do not suffer any detrimental effect on reproductive fitness 
(McCaughey & Hart, 2000). The mechanisms which support hantavirus persistence 
in reservoir hosts have not been clearly defined. One major hypothesis suggests that 
hantaviruses maintain persistence in the host by supressing the immune responses 
required to clear infection (Easterbrook et al, 2007). Another possible persistence 
mechanism is replication in immune cells such as monocytes, macrophages and T 
lymphocytes. Hantaviruses also probably avoid detection by the host immune 
system by regulating viral replication and viral protein expression (Meyer & 
Schmaljohn, 2000).  
Human epidemics can be predicted by the cyclic fluctuations on reservoirs 
populations; a recent study showed a direct correlation between an increase in bank 
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vole population in previous spring and human cases in the autumn of Nephropathia 
epidemica (Kallio et al, 2009). The outbreak of epidemics in humans is closely 
correlated to increased reservoir population. In central Europe the increase in rodent 
populations occurs due to mast years. A mast year is a year when there’s increased 
abundance in tree nuts on the forest floors, a food source for rodents. This increase 
in food source can be attributed to high summer temperatures 2 years prior and high 
autmun temperature in the previous year; these high temperatures favour flower and 
seed development which then results increased nut production. Increased food 
source during mast years results in increased rodent population, enough to maintain 
transmission of the virus within the population and to humans (Jonsson et al, 2010). 
The similar phenomenon is observed in North America, where increased 
precipitation leads to increased food resources for the rodents and an increase in the 
reservoir population (Engelthaler et al, 1999).  
2.6 Epidemiology  
Hantaviruses that cause human infection and disease are hosted by rodents. There 
is no solid evidence that insectivore-hosted viruses cause disease in humans. 
Human beings are primarily infected by aerosolised rodent faeces, urine and saliva 
(Vaheri, 2008), but humans have also been infected through contact with open 
wounds and rodent bites (Hammerbeck et al, 2008).  
The discovery of HTNV as the causative agent of Korea haemorrhagic fever (KHF) 
led to epidemiological studies in rodents and humans (Jonsson et al, 2010). 
Infections in humans are not age- or gender dependent. All exposed indivduals have 
the same risk of infection and disease. However, epidemiological studies show that 
most cases of both HFRS and HCPS occur in working-age males. This phenomenon 
is most likely related to occupational exposure: agricultural or forest work where 
individuals are most likely to come into contact with infected animals (Hammerbeck 
et al, 2009).  
There are an estimated 150 000 to 200 000 HFRS cases per year; 100 000 of which 
occur in China (Maes et alet al, 2004; Bi et al, 2008). Clinical cases have been 
reported in other Asian countries such as Taiwan and South Korea (Bi et al, 2008). 
In Europe, HFRS is caused by DOBV, PUUV and TULV. DOBV predominantly 
occurs in the Balkans and Eastern Europe, and it is the most virulent European virus 
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with a mortality rate of up to 12% (Maes et al, 2004). PUUV has the widest 
geographical range in Europe, human infection results in Nephropathia epidemica, a 
milder form of HFRS with a case fatality rate of 0.1% (Clement et al, 2007).The first 
reported outbreak of hantavirus disease in the Americas was in 1993; disease 
outbreak occured in the four corners region in the USA. The causative agent was Sin 
Nombre viurs (SNV) hosted by Peromyscus Maniculatus. The first HCPS case in 
South America was reported in Argentina caused by the Andes virus, in 1995 with 29 
cases reported (Bi et al, 2008). Andes virus is the only hantavirus for which person-
to-person transmission was reported (Martinez et al, 2005).  
Serological evidence of hantavirus infections (in both humans and rodents) in Africa 
was found in 1984 by Gonzalez et al. serological surveys were done in Central 
African Republic, Gabon, Benin and Brukina Faso.  Evidence of human hantavirus 
infections was also found in Egypt, Nigeria, Djibouti and Senegal (Bi et al, 2008). 
Only one case was reported in Africa; in the Central African Republic in 1987 
(Coulaud et al, 1987). The first African hantavirus was identified in Guinea, west 
Africa. It was named Sangassou (SANGV) after the village near which the host was 
trapped (Klempa et al, 2006).  A follow-up study was done in Guinea in 2009. The 
prevalence of hantavirus antibodies was 1.2% and Sangassou specific antibodies 
were found in 2 patients (Klempa et al, 2010).          
                                                                                                                                                
2.7 Hantavirus Disease 
Hantaviruses cause disease in humans but not in their animal hosts. No hantavirus 
disease has been reported in other animals, but experimental infection of hamster 
has been done to study the HCPS disease progression (Milazzo et al, 2002). Both 
the pathogenic and non-pathogenic viruses have the same tissue tropism. They 
mainly replicate in the endothelial cells and macrophages (Maes et al, 2004). In both 
HFRS and HCPS viraemia is thought to occur subsequent to infection of alveolar 
macrophages, resulting in the infection of kidney and lung endothelial cells (Maes et 
al, 2004). There are disease features common to both HFRS and HCPS; increased 
vascular permeability (which results in hypotension, hemoconcentration and 
vasodilation), increased TNF-α production, acute thrombocytopenia, CD8+ T 
lymphocyte activation,  and leukocytosis (Schönrich et al, 2008; Vaheri, 2008). The 
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primary target in HFRS is the kidneys but pulmonary involvement has been reported 
in patients and the same is true for HCPS were the lungs are the primary target and 
renal involvement occurs as well (Vaheri, 2008).  
 
2.7.1 Haemorrhagic Fever with Renal Syndrome 
HFRS disease presentation ranges from febrile disease to fulminant haemorrhagic 
shock and death. The incubation period for HFRS ranges from 10 days to 6 weeks 
and the average is 3 weeks. The severity of disease and clinical pattern vary from 
subclinical to fatal. HFRS caused by HTNV, Amur virus and DOBV is more severe, 
while SEOV is more moderate and PUUV causes mild Nephropathia epidemica 
(Jonsson et al, 2010). Febrile phase begins abruptly accompanied by headache and 
myalgia. This phase lasts 3 to 7 days and 11 to 40% of patient progress to the 
hypotensive phase (McCaughey & Hart, 2000; Jonsson et al, 2010).  During this 
phase this patients experience thirst, restlessness, nausea and vomiting which lasts 
for hours or days. Thrombocytopenia, petechial haemorrhages, proteinuria, 
conjunctival injection and acute myopia may occur (Jonsson et al, 2010). The 
decrease in blood pressure due to vascular leakage may result in fatal shock 
syndrome. After 3 to 7 days, the oliguric begins and it is characterised by decrease 
in kidney function resulting in oliguria (or anuria), proteinuira, abnormal urinary 
sediment, including microscopic hematuria, and azoturia (Schönrich et al, 2008). 
Blood pressure may return to normal though patients are at risk of developing 
hypertension and pulmonary oedema (McCaughey & Hart, 2000; Jonsson et al, 
2010). Dialysis is required for 20% of SEOV patients and 40% of HTNV patients 
(Jonsson et al, 2010). The oliguric phase lasts for 3 to 7 days. Urinary output 
increases during the diuresis phase and patients can pass up to several litres of 
urine per day for several weeks (McCaughey & Hart, 2000). Convalescence is 
prolonged and it is several months before the patients fully recover. The mortality 
rate for HFRS ranges from 5% to 15% for HTNV and DOBV (Schönrich et al, 2008). 
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2.7.2 Nephropathia Epidemica 
Nephropathia Epidemica (NE) is a milder form of HFRS. It mainly occurs in 
Scandinavia and Central Europe, and is mainly caused by PUUV or SAAV. The 
incubation period before onset of symptoms ranges from 1 to 5 weeks (Pettersson et 
al, 2008). More than 90% of NE cases are asymptomatic and case fatality ranges 
from 0.1-1% (Vaheri, 2008; Hammerbeck et al, 2009). NE patients usually present 
with high fever, headache, backache, and abdominal pain (Muranyi et al, 2005). NE 
may also present with conjunctival haemorrhages, petechiae and truncal rash 3 to 4 
days after onset of symptoms. Approximately 1% of NE patients develop severe 
neurological complications such as bladder paralysis or seizures (Muranyi et al, 
2005; Hammerbeck et al, 2009). A 3 day oliguric phase is followed by polyuria and 
convalescence extends over several weeks, but sequelae are rare (Hammerbeck et 
al, 2009).  
2.7.3  Hantavirus Cardiopulmonary Syndrome 
Hantavirus cardiopulmonary syndrome (HCPS) initially presents with a prodromal, 
febrile phase that lasts 3-5 days. Patients initially present with flu-like nonspecific 
symptoms such as fever, myalgia, malaise, headache, abdominal pain, nausea, 
vomiting, and sometimes a transient skin rash and conjunctival suffusion (Muranyi et 
al, 2005). The start of the cardiopulmonary phase which is marked by the non-
productive cough, shortness of breath, and tachypnea are as a result of pulmonary 
oedema, respiratory failure and cardiogenic shock (Hammerbeck et al, 2009). The 
mortality rate during this phase is 50% for SNV and ANDV, and patients who survive 
enter the diuretic phase; rapid clearance of the pulmonary oedema and dieresis 
occurs. The convalescent phase that follows is marked by fatigue and abnormal 
pulmonary function but full recovery usually occurs (Hammerbeck et al, 2009).  
2.8 Hantavirus Pathogenesis 
No main factor has been identified to explain the pathogenesis of HFRS and HCPS 
(Gavrilovskaya et al, 1999; St Jeor et al, 2005). Evidence from infected patients and 
experimentally infected hamsters suggests that hantaviruses primarily target 
endothelial cells (Hammerbeck et al, 2009). Studies in which Vero E6 cells, human 
umbilical cord vein endothelial cells and CHO cells were transfected with 
recombinant integrins indicate that β3 integrins facilitate the entry of pathogenic 
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HCPS-associated hantaviruses (Gavrilovskaya et al, 1998). Similar experiments 
were also performed to determine the receptors that mediate cellular entry of HFRS-
causing hantaviruses, in which the ability of ligands and antibodies to inhibit infection 
of endothelial cells, vero E6 cells and β3-integrin transfected CHO cells by Puumala, 
Seoul Hantaan and Prospect Hill viruses. Results showed that Vitronectin was the 
most effective inhibitor of PUU and SEO infection but was less effective against HTN 
and had no effect on PH. Results from these experiments suggest that β3-integrins 
mediate entry of HFRS-causing hantaviruses, it also suggests that additional cell 
surface interactions contribute to hantavirus entry as uninhibitable hantavirus 
infectivity was observed (Gavrilovskaya et al, 1999). In contrast, the entry of non-
pathogenic PHV is not mediated by β3-integrins; PHV infectivity was inhibited by α5-
antibodies and β1-antibodies which suggest that PH cellular entry is mediated by 
α5β1-integrin receptors (Gavrilovskaya et al, 1999; 2002). 
The course of infection and severity of hantavirus disease is determined by the 
degree of increased permeability of the infected endothelial cells. The mechanism by 
which pathogenic hantaviruses induces capillary leakage during the acute phase of 
both HFRS and HPS is not yet fully understood (Muranyi et al, 2005). However, 
experimental results from Gavrilovskaya et al suggest that hantavirus infection 
inhibits β3-integrin-directed endothelial cell migration (Gavrilovskaya et al, 2002). 
The αvβ3-integrin receptor is a heterodimeric receptor composed of α and β subunits 
that are responsible for cell-to-cell adhesion, cell migration, Ca2+ channels 
(regulation of arteriolar smooth muscle), extracellular matrix protein recognition and 
platelet aggregation (Gavrilovskaya et al, 1999; Gavrilovskaya et al, 2002; Maes et 
al, 2004). The αvβ3-integrins are abundant surface receptors of endothelial cells, 
platelets and macrophages and the interaction of between the αvβ3-integrins and 
hantaviruses provides the potential for dysregulation of normal endothelial cell 
functions and contributing to increased vascular permeability observed in hantavirus 
diseases (Gavrilovskaya et al, 2002).  
The exact mechanism by which hantavirus infection results in vascular permeability 
is unkonwn  as In vitro experiments show that hantavirus infection does not cause 
visible cytopathic effect in target cells, nor does it cause changes in the permeability 
of the endothelial layer, and  investigation of postmortem tissue from infected 
patients does not show visible endothelium damage (St Jeor et al, 2005). 
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Experimental evidence from in vitro studies by Gavrilovskaya et al, suggests that 
pathogenic HCPS- and HFRS-causing hantaviruses both enter the target cells via  
β3-integrin receptors (Gavrilovskaya et al, 1998; Hammerbeck et al, 2009). This 
suggests that pathogenesis is multifactorial and is attributed to the direct effect of the 
virus on the host cell, the production of TNF-α by infected macrophages and 
cytotoxic effect of hantavirus specific CD8+ T lymphocytes (CTLs) on infected cells 
(St Jeor et al, 2005; Terajima et al, 2007; Jonsson et al, 2010). In vivo and in vitro 
studies have showed that there are increased cytokine levels during hantavirus 
infection (Vapalahti et al, 2001; St Jeor et al, 2005). TNF-α reach highest level in 
plasma of HFRS-infected patients 3 to 5 days after the onset of disease, and lung 
and kidney biopsies showed a high number of TNF-α positive cells (St Jeor et al, 
2005). Experimental evidence suggests that overproduction TNF-α may result in 
severe systemic toxicity; additionally it may act as a mediator of septic shock 
(Vapalahti et al, 2001) as well as capillary leakage. Experimental data from 
Hayasaka et al suggests that SNV-specific CTLs contribute to the capillary leakage 
that is observed in HCPS disease (Terajima et al, 2007). The role of CTLs in 
increasing capillary permeability was illustrated using the transwell permeability 
assay were an SNV-infected endothelial cell line was exposed to SNV-specific CTLs. 
CTL induced permeability is probably due to production of cytokines such as TNF-α 
by CTLs rather than cell lysis as autopsies from fatal HCPS cases show no visible 
damage to endothelial cells (Hayasaka et al, 2007).  Higher frequency of CTLs were 
observed in hospitalized patients with clinically severe SNV-HCPS disease requiring 
mechanical ventilation compared to those who had mild disease (Kilpatrick et al, 
2004).  
Our understanding of hantavirus pathogenesis is limited by the absence of disease 
in reservoir hosts and the lack of an animal model. The analysis of cellular 
differences that might be associated with the viral phenotypes that determine 
pathogenicity and non-pathogenecity is hampered by the lack of cell lines from hosts 
(Gavrilovskaya et al, 1998; 2002; Mackow & Gavrilovskaya, 2001 
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2.9 Immune Response 
Innate response occurs in response to hantavirus infection of the host cell. 
Expression of various type I interferon and other proinflammatory cytokines as well 
as the activation of interferon inducible genes is required for the induction of cellular 
viral resistance and activation of innate immune cells such as Natural killer cells 
(Schönrich et al, 2008). Studies have shown the expression of MxA protein is 
delayed in cells infected with pathogenic virus compared to the cells infected with 
non-pathogenic virus. The same phenomenon was observed for the upregulation of 
HLA class I molecules. Other antiviral mechanisms such as the classical and 
alternative route of the complement system are also activated during infection 
(Muranyi et al, 2005).  
 
All types of Immunoglobulins are expressed during HFRS- and HCPS- causing 
hantavirus infection. The main target of antigen in the N protein but antibody titres 
against the glycoproteins G1 and G2 are also produced (Kanerva et al, 1998; 
Muranyi et al, 2005). IgA is detected during the acute phase of disease; however the 
anti-viral protection mechanism in human infection is unknown. Studies in rats have 
shown that maternal IgA protect the infants from lethal doses of SEOV (St Jeor et al, 
2005). IgE serum levels are increased during infection and it is hypothesized that IgE 
plays a role in hantavirus pathophysiology by activating the secretion of IL-1β and 
TNF-α which influence permeability of the infected endothelium (Muranyi et al, 
2005). IgM antibodies have been observed against all three viral structural proteins 
and it is detected during the acute phase of infection and levels decline during the 
convalescent phase coinciding with the increased levels of IgG (Kanerva et al, 1998; 
St Jeor et al, 2005). IgG titre is higher for G1 and G2 than N protein (St Jeor et al, 
2005).  
Cytotoxic CD8+ T lymphocytes (CTLs) are the predominant lymphocyte present 
during a hantavirus infection (Muranyi et al, 2005) as they have been detected blood 
samples obtained from infected animals as well as patients in convalescence 
(Kanerva et al, 1998). CTLs play an important role in the clearance of the infection 
and in pathogenesis of HFRS and HCPS (Muranyi et al, 2005). Studies by Kilpatrick 
et al show that the severity of HCPS disease correlates with the number of CTLs. 
Using flow cytometry, they illustrated the relationship between the frequency of 
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CD8+ cells (as well as increased presence of TNF-α, IFN-γ and IL-2 producing cells 
in the lungs of HCPS patients) and severity of disease (Kilpatrick et al, 2004).  
CTL epitopes have been identified for the three viral structural proteins; Glycoprotein 
1 (Gc), Glycoprotein 2 (Gn) and Nucleoprotein (N) which is the major antigen 
responsible for the activation of the T cell response during infection (Muranyi et al, 
2005; St Jeor et al, 2005).  
 
2.10  Diagnosis of Hantavirus Infection 
The diagnosis of hantavirus infection in human beings is based on clinical and 
epidemiological information as well as laboratory tests. A definite diagnosis cannot 
be based solely on clinical findings especially in cases were disease is mild to 
moderate (Bi et al, 2008). Testing should be performed on samples from patients 
with fever of unknown origin, lumbago, renal failure, respiratory distress and recent 
outdoor activities during which there was possible exposure to rodents and shrews 
or their excreta (Muranyi et al, 2005).  
Diagnosis of hantavirus infection is mainly based on serological testing because 
viremia is short-lived and viral RNA cannot consistently be detected in human blood 
and urine specimens. PCR has been used successfully in detecting PUU RNA in 
some patient specimens, but the short duration or absence of viraemia during the 
acute phase of infection means that other methods must be used for patient 
diagnosis (Sjölander & Lundkvist, 1999). 
Serology is ideal because high levels of virus-specific antibodies can be detected at 
the onset of disease (Vapalahti et al, 2001; Bi et al, 2008); the highest antibody titres 
are observed between day 8 and 25 (Muranyi et al, 2005). One of the first serological 
tests in Europe and Asia was indirect immunofluorescence assay (IFA) using 
hantavirus-infected cells (fixed on microscope slides) as antigen (Jonsson et al, 
2010). However using infected cells in a diagnostic assay has its disadvantages as 
BSL-3 conditions are required for cell culture infections (Bi et al, 2008). Thus most 
serological assays consist of recombinant hantavirus proteins N, Gn and Gc protein 
as antigens but most assays are based on the recombinant N protein as the N 
protein is the most abundant viral protein which also induces a strong humoral 
response in both humans and rodents (Jonsson et al, 2010). Other assays such as 
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Enzyme immunoassay and western blot are used for diagnosis but IgG and IgM 
indirect enyme-linked immunosorbent assay (ELISA) is the most common. The 
detection of IgM is important for the diagnosis of acute infection especially in areas in 
which hantavirus infection is endemic and there is a high prevalence of IgG in the 
population due to previous infection (Bi et al, 2008).  
Although the above assays are ideal for in determining whether a patient is infected 
with hantavirus, none of these tests can determine which hantavirus is responsible 
for the infection as significant humoral cross-reaction occurs between the different 
hantaviruses (Bi et al, 2008; Jonsson et al, 2010). The infecting hantavirus can only 
be serotyped by the focus reduction neutralisation test (FRNT) which is the gold 
standard for hantavirus testing (Vapalahti et al, 2001; Bi et al, 2008). FRNT can 
detect and measure neutralizing antibodies by comparing serum titres to the relevant 
hantaviruses (Vapalahti et al, 2001; Jonsson et al, 2010) and though it is capable of 
distinguishing hantaviruses with serum from experimentally infected rodents it was 
found to be less specific when serum from acute phase patients was tested (Jonsson 
et al, 2010) other drawbacks of FRNT is that it (i) is time-consuming and labour-
intensive, and (ii) must be carried out under BSL-3 conditions because infected cell 
cultures are used in the assay (Vapalahti et al, 2001; Bi et al, 2008).  
The identification of the hantavirus responsible for infection can also be achieved by 
molecular methods such as virus-specific RT-PCR (Bi et al, 2008; Jonsson et al, 
2010), however virus-specific assays can only be used if the suspected agent is 
known beforehand. Therefore, RT-PCR using universal primers to recognise most or 
all members of the genus may be used and the suspected species of virus is 
genotyped by sequencing. RT-PCR can be used detect RNA from fresh/frozen 
tissue, blood and serum (Bi et al, 2008). RT-PCR can be useful as a rapid method 
for hantavirus detection in HCPS cases where disease is fast-evolving; patients can 
evolve from acute illness to severe pneumonia and respiratory disease in 12 to 24 
hours (Jonsson et al, 2010). One-step assays with proven specificity, sensitivity and 
reproducibility have been developed for hantavirus detection based on real-time RT-
PCR and results can be obtained within 24 hours it must be note however that PCR 
is only useful in the early stages of infection when patients are viremic (Bi et al, 
2008). Virus isolation from human samples is very rare; it is therefore not considered 
an option in the diagnosis of human hantavirus infection (Bi et al, 2008).  
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2.11 Prevention and Treatment of Human Hantavirus Infections 
Treatment for hantavirus infection in humans is supportive to keep symptoms in 
control as no effective antiviral drug has been developed as yet (Muranyi et al, 2005; 
St Jeor et al, 2005). Effective treatment is achieved by careful fluid management, 
control of electrolyte balance and hemodynamic monitoring (St jeor et al, 2005). 
Patients with HFRS and HCPS are supervised in an emergency medicine or 
intensive care unit until the virus is cleared and convalescence begins (Muranyi et al, 
2005).  
There are no antiviral drugs or immunotherapeutic agents that are FDA approved for 
the treatment of hantavirus infection (Hammerbeck et al, 2009). Evidence from In-
vitro and animal studies suggests that ribavirin has the ability to inhibit hantavirus 
replication (McCaughey & Hart, 2000). Ribavirin has been used in the treatment of 
HFRS patients in China. Ribavirin was able to reduce viral titres, increase survival 
rates and reducing the severity of disease in patients (Hammerbeck et al, 2009; 
Jonsson et al, 2010). However, ribavirin trials on HCPS patients have no effect on 
the outcome of disease. The negative results observed might be because patients 
were treated after the onset of the cardiopulmonary phase where as HFRS patients 
were treated before the onset of renal complications. This evidence suggests that 
the efficacy of ribavirin is dependent on the phase of infection and severity of 
disease at the time of administration (Hammerbeck et al, 2009). Studies in China 
have shown that α-interferon has no effect on mortality or the clinical course of 
HFRS (McCaughey & Hart, 2000).    
A variety of hantavirus vaccines has been developed using to main approaches; 
inactivated virus and subunit molecular virus vaccines (McCaughey & Hart, 2000). 
Inactivated virus vaccines include viruses replicated in rodent organs or cell culture, 
the virus is then chemically inactivated with 0.05% of formalin or β-propiolactone and 
then combined with an adjuvant (Hammerbeck et al, 2009). Inactivated-virus 
vaccines based on HTNV, PUUV and SEOV have been produced and tested in 
humans in China and Korea (Table 2.2). 
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Table 2.2 Inactivated virus vaccines currently authorised for use in China and Korea. 
[Source: Bi et al, 2008]. 
 
There are four types of subunit molecular vaccines: protein-based, DNA, virus-like 
particles, live-virus vectored as well as packaged replicons. Protein vaccines are 
produced by recombinant baculovirus, E. coli, yeast and transgenic plants. In most of 
the studies performed in animal models, humoral and cellular immune responses 
were observed. The study by Schmaljohn et al in hamsters, is the only one published 
that investigated the immunogenicity and protective efficacy of purified recombinant 
glycoproteins in subunit vaccines and found that the best results were observed in a 
vaccine that includes both Gc and Gn. In another study by Bharadwaj et al in 2002, 
results indicated that the highest level of protection was elicited with Gn peptides. Of 
all the known subunit molecular vaccines only DNA vaccines have been tested in 
non-human primates; Custer et al and Hooper et al tested a HCPS DNA plasmid 
vaccine based on ANDV M gene segment. High levels of neutralizing antibodies 
were observed in macaques and rabbits (Hammerbeck et al, 2008). 
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The most effective means of control of hantavirus disease is to minimise human 
exposure to infected rodents and their excrement. Monitoring hantavirus prevalence 
in local rodent populations may give some warning to expected increase in the 
incidence of human cases.  Exposure can be minimised by following measures such 
as rodent-proofing of homes and workplaces (in agriculture and forestry), minimize 
food available for rodents, adequate disposal of dead rodents (McCaughey et al, 
2000; Bi et al, 2008). 
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CHAPTER 3 
3 Materials and Methods 
 
3.1 Animal Specimens 
3.1.1 Ethical Approval 
Ethical approval for the testing of animal organs for hantaviruses was obtained from 
the Faculty of Health Sciences' Committee for Experimental Animal Research 
(CEAR). Project number P09/02/001 was assigned to the study. 
Ethical approval for trapping by Dr Sonja Matthee (Department of Conservation 
Ecology and Entomology) was obtained from the Faculty of Science Ethical 
committee (2006B01007). 
3.1.2  Animal Trapping  
Permits for the trapping of small mammals were obtained from the relevant 
authorities: Cape Nature (Permit No. AAA 004-00034-0035), and the Department of 
Tourism, Environment and Conservation of the Northern Cape Province (Permit No. 
2268/2007).  
Trapping was conducted by Dr Sonja Matthee and her research team for the study of 
macroparasites in various rodents in Southern Africa. The animals were also used 
for other non-virological research projects. Animals were trapped at selected sites in 
the Western Cape and Northern Cape Provinces representing different biomes and 
vegetation types: Fynbos, Succulent Karoo, desert, Dwarf shrub and mixed tree 
shrub (Matthee et al 2009).  
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Figure 3.1 South African biomes. 
A map of South Africa illustrating the different biomes within the country. Trapping was 
conducted in the Western Cape and the Northern Cape provinces, which consist of desert, 
Fynbos, succulent karoo, nama-karoo and desert [Source: 
http://www.environment.gov.za/enviro-info/nat/biome.htm ] 
 
Animal trapping was also conducted close to and within rural and urban areas, and 
on farms close to human dwellings. Adult rodents and shrew were mainly targeted as 
previous studies have shown that the highest antibody prevalence is associated with 
older animals. 30 adult animals with a body mass of at least 40g were trapped per 
locality. Trapping was done during reproductively active season for rodents and 
shrews which is mainly during spring and summer. Studies have shown that fighting 
and biting during the breeding season facilitates the transmission and since male 
animals tend to be more aggressive towards competing males during the breeding 
season (Hinson et al, 2004; Douglass et al, 2007), this increases the chances of 
recording positive animals. 
Sherman-type live-traps were used in a standardized grid system over a period of 7 
to 14 days per locality; wherever possible the traps were placed in the shade under 
shrubs or trees to minimise exposure of the animals to direct sunlight preventing the 
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animals from suffering extreme heat or cold. The traps were baited with a peanut 
butter-oats mixture and checked twice daily (mornings and afternoons) to optimise 
trapping success (Matthee & Krasnov, 2009).  
Non-targeted species were identified and released unharmed at the trapping site. 
Targeted species were immediately euthanized by intra-peritoneal injection with 
200mg/kg of Sodium Pentobarbitone, placed in pre-labelled plastic bags and stored 
in a field freezer. Once back at the laboratory the animals were stored at -80°C until 
dissection. 576 animals were trapped at different localities in the Western Cape 
Province, Northern Cape and Namibia, from 2007 to 2010 (Addendum C).  
Animals were dissected and organs removed by Dr Matthee’s team and transported 
on ice to the Division of Medical Virology at Tygerberg Campus. Upon arrival the 
samples were catalogued (specimen number and trapping location was recorded) 
and stored at -80°C to await RNA extraction and tes ting.  
3.1.3  Tissue Disruption and Homogenisation 
After thawing, ~20mg of lung tissue was cut from stored lung and chopped into small 
pieces using No.10 scalpels, which can fit into 2ml tube, and 350µl of Qiagen RLT 
buffer, a highly denaturing buffer which contains guanidine-thiocyanate which 
inactivates RNase to maintain the integrity of RNA in the samples was added to the 
sample. The mixture was then drawn in and out of a 2ml syringe to homogenise it. 
The homogenised samples were then placed in QIAshredder columns from Qiagen 
(Germany) and centrifuged for 5 minutes at 14000 rpm to remove debris. 
Supernatant for each sample was then placed in 2.0ml tubes compatible with the 
QIAcube extraction machine for RNA extraction. 
3.1.4  RNA Extraction 
Total RNA was extracted automatically from the supernatant prepared for each 
sample during the tissue disruption and homogenisation process, using the RNeasy 
mini kit on the QIAcube platform (Qiagen, Hilden, Germany) using the 
manufacturer's standard protocol for total RNA extraction from animal cells and 
tissue (www.qiagen.com/qiacube/standard/protocolview.aspx?StandardProtocolID=794). 
The procedure is based on a technology that combines the selective binding 
properties of silica membranes with the speed of microspin technology. After the 
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tissue was lysed and homogenised in the presence of RLT buffer; Ethanol was then 
added in order to facilitate the binding of the RNA to the silica membranes in the 
columns. Contaminants were then washed from the washed away and the RNA was 
eluted in 50µl of RNase-free water.  
3.1.5  Hantavirus Screening 
3.1.5.1 Preparation of Positive Control 
Virus was grown under BSL-3 conditions in Vero E6 cells in 25cm2 flasks in MEM 
containing 10% foetal calf serum, L-glutamate, penicillin and streptomycin. The 
medium was then changed weekly and two-thirds of the cells were trypsinised at 3-
week intervals and passaged into new flasks. Fifty percent uninfected cells were 
added to the infected cell culture to make a 1:1 mixture. The cultures were then 
analysed at 7 day intervals by immunofluorescence assay (IFA) using hantavirus-
specific monoclonal antibodies 4C3 and 1C12 at 5µg/ml since hantavirus infection 
does not cause visible cytopathic effect in infected cells (Razanskiene et al, 2004). 
The cells were first fixed with acetone onto a glass slide, and monoclonal antibodies 
were added and then incubated for 30 minutes at 37°C. Fluorescin isothiocyanate 
(FITC) conjugated rabbit anti-mouse antibodies were added to the slide and 
incubated for 30 minutes at room temperature, washed with PBS and viewed under 
fluorescence microscope. Cell cultures positive for hantavirus antigens were 
centrifuged at and the cell culture supernatant was stored at -80°C and extracted at 
later stage (Nemirov et al, 1999). 
RNA was extracted from cell culture supernatant manually using the RNeasy mini kit 
from Qiagen (Germany). The RNA was reverse transcribed using the M-MLV reverse 
transcriptase kit from Invitrogen (USA). Reaction volume was 20µl with 10µl RNA 
template, 4µl 5× First Strand buffer, 0.5µl 200U/µl Moloney murine leukemia virus 
(M-MLV) reverse transcriptase, 0.5µl random hexamer primer(Bioline, Germany), 
0.1µl 0.1M dithiothreitol, 3µl 10mmol/L dNTP mix from Bioline (Germany) 0.5µl 
40U/µl Ribolock RNase inhibitor()and 1.4µl nuclease-free water from Qiagen 
(Germany). The RNA was then incubated under the following conditions: 25°C for 10 
minutes, 42°C for 10 minutes and 96°C for 6 minutes  on the 9700 GeneAmp® PE 
cycler from Applied Biosystems (California, USA). 
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3.1.5.2  cDNA Synthesis 
Reverse transcription was performed using the M-MLV reverse transcriptase kit from 
Invitrogen (USA). The M-MLV RT uses single-stranded RNA as a template to 
synthesise cDNA in the presence of primer; Random Hexamer primers from Bioline 
(Germany) were used for reverse transcription, which was run on the GeneAmp 
9700 PE from Applied Biosystems (California, USA) under the following conditions: 
25°C for 10 minutes, 42°C for 10 minutes and 96°C f or 6 minutes. Reaction volume 
was 20µl; 8µl RNA of each sample, 4µl 5× First strand buffer, random hexamer 
primers (Bioline), 0.5µl 200U/µl M-MLV RT, 0.1M DTT, dNTP mix (Bioline), 40U/µl 
Ribolock RNase inhibitor (Fermentas, UK)and 1.9µl nuclease-free water (Qiagen, 
Germany).  
3.1.6   Pre-nested and Nested Amplification 
Amplification was carried out using the primers from Klempa et al, 2006 (Table 2.1). 
The degenerate primers were designed to target a conserved in region in the L-
segment nucleotide sequence and to detect known and unknown members of the 
Hantavirus genus (Klempa et al, 2006). Prenested amplification was carried out 
using the forward primer HAN-L-F1 and reverse primer HAN-L-R1 producing a 
~412bp fragment.  
Reaction volume was 25µl with 5µl cDNA added to 12.5µl Thermo-Start™ PCR 
master mix from Thermo Scientific (UK) containing a chemically modified Taq DNA 
polymerase a hot-start enzyme which remains inactive at room temperature and 
requires activation at 95°C for 15 minutes, 0.2mM d NTPs and 1.5mM MgCl2, 5µl 
forward primer, 5µl of reverse primer, 1µl MasterAmp™ 10× PCR enhancer from 
Epicentre® Biotechnologies (Wisconsin, USA) and 2.0µl of nuclease-free water 
(Qiagen, Germany) and amplification done on the 9700 PE Applied Biosystems with 
the following cycling conditions: 95°C for 15 minut es, 95°C for 30 seconds, 53°C for 
45 seconds and 72°C for 40× cycles, and 72°C for 6 minutes.  
For nested amplification the forward primer HAN-L-F2 and reverse primer HAN-L-R2 
were used to produce a ~390bp fragment. The total reaction volume was 50µl; 1µl 
prenested product was added to 25µl Thermo-Start™ PCR master mix, 5µl forward 
primer, 5µl of reverse primer, 1µl MasterAmp™ 10× PCR enhancer and 13µl of 
nuclease-free water. Amplification reactions carried out at the following cycling 
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conditions: 95°C at 15 minutes, 95°C for 30 seconds , 53°C for 45 seconds, 72°C for 
30 seconds for 25× cycles and 72°C for 6 minutes.  
Reverse transcription, pre-nested and nested amplification were carried out in 0.2ml 
8 strip, thin-walled PCR tubes from Axygen (USA). 
Table 3.1 PCR primers for the pre-nested and nested amplification  
The primers target the conserved region of the L-segment.  
Primers Sequences (5’→3’) 
HAN-L-F1 ATG TAY GTB AGT GCW GAT GC 
HAN-L-R1 AAC CAD TCW GTY CCR TCA TC 
HAN-L-F2 TGC WGA TGC HAC IAA RTG GTC 
HAN-L-R2 GCR TCR TCW GAR TGR TGD GCA A 
 
3.1.7  Gel Electrophoresis 
Nested PCR products were visualized on 1% (m/v) agarose gel. Five hundred 
millilitres 0.05M EDTA solution, pH 8.0 was prepared from 146.1g EDTA (Sigma 
Aldrich, USA) and distilled water,. 10M NaOH (Merck, Germany) was used to adjust 
the pH and the solution was then autoclaved at 121°C for 1 hour. 50× TAE buffer 
was prepared using 57.1 ml of glacial acetic acid (Merck Chemicals, Germany), 242g 
Tris base (Boehringer Mannheim, USA), 100ml of 0.05M EDTA and distilled water. 
The 1% agarose was prepared by mixing 1g of LE agarose (Promega, USA) and 
99ml of 1× TAE buffer; the mixture was microwaved on high for 3 minutes and then 
poured into an electrophoresis tray and allowed to set for at least 30 minutes. The 
electrophoresis buffer (1× TAE) was added to the tray to submerge the gel. Samples 
were loaded using 6× orange/blue loading dye (Promega, USA) and a 100bp ladder 
(Bioline, Germany) was used as the molecular marker. Five microlitres of 0.05 mg/µl 
ethidium bromide (Promega, USA) was added to the electrophoresis buffer (1×TAE) 
and a power supply of 60V was used for electrophoresis for approximately 45 
minutes.  
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3.1.8  Visualisation of PCR Product 
Nested PCR product was visualised on the UVItec Alliance (Chemiluminscence and 
Fluorescence system) (Cambridge, UK) using the UVIchemi image acquisition 
system to capture the gel images by exposing the gels to UV light at 254nm to 
visualise the PCR products, the expected band size  is ~390bp.  The images were 
then enhanced and edited using UVIband software, and saved.  
3.2 Screening of Human Specimens 
3.2.1 Ethics Approval 
Ethical approval for recruitment of patients from Tygerberg hospital and Groote 
Schuur hospital was obtained from the Stellenbosch University  Human Research 
Ethics Committee (HREC) (Ethics Reference No: N09/02/058) (Addendum D).  
3.2.2 Sampling 
3.2.2.1 Patients with Acute, Suspected Hantavirus-related Disease 
A surveillance system for patients expressing the symptoms associated with possible 
hantavirus infection was established with the help of infectious disease, renal and 
pulmonology physicians at the participating hospitals. Patients who fulfilled a clinical 
definition of possible hantavirus disease were recruited to the study: fever of 
unknown origin, i.e. not responding to antibiotic treatment, plus any of the following 
also with unknown cause: acute renal failure, acute respiratory failure, acute liver 
failure, or mucosal bleeding. Patient data such as date of birth, place of residence, 
symptoms and location of potential exposure to rodents are recorded and 10ml of 
blood collected in yellow- top Silica Clot Activator vacutainer tubes (BD Biosciences). 
3.2.2.2 Opportunistic (convenience) Serosurvey  
This survey is conducted using residual patient serum samples sent to NHLS 
laboratories in the Western Cape for routine laboratory testing that are leftover after 
the requested tests are completed. The samples being used would otherwise have 
been discarded. Since the purpose of screening these samples was determine 
whether Hantavirus antibodies are present in the population, samples were 
anonymised upon receipt and no information on demographics or medical 
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information on the patient was recorded. However, source laboratory, age and sex 
were recorded. 
3.2.3 In-house Indirect ELISA 
An indirect ELISA was set up according to published protocols (Dargeviciute et al, 
2002; Razanskiene et al, 2004) to detect hantavirus-specific IgG antibodies using 
recombinant N protein from Puumala and Dobrava viruses. Neither of these viruses 
has been isolated in Africa but these antigens are available and it can be expected 
that there will be some degree of antibody cross-reactivity where antibodies against 
a specific virus are able to bind to corresponding antigens of viruses closely related 
to the one that induced the antibody production (Elgh et al, 1998).  
The N protein has a molecular weight of about 50kDa and contains 429 to 433 amino 
acid residues (Kaukinen et al, 2005). It is the most abundant hantavirus protein 
synthesized during the early steps of infection. A primary function of the N proteins is 
to protect the RNA genome from nuclease degradation. The N protein in the in the 
ribonucleoprotein (RNP) interacts with the cytoplasmic tail of the Gc to initiate virion 
assembly (St Jeor et al, 2005). Studies in humans and animal models have shown 
that the N protein is highly immunogenic (Dargeviciute et al, 2002).  
3.2.4  Expression of Recombinant N Protein  
The expression and preparation of the recombinant nucleoproteins for the Dobrava 
and Puumala viruses was done at the Institut für Med. Virologie, Chaité 
Universitätsmedizin, Berlin, Germany.  
The open reading frames for the N protein for the Puumala and the Dobrava viruses 
were cloned separately into the pFX7, a yeast expression vector. pFX7 contains 
formaldehyde resistance gene and expression of the N protein is under the control of 
the hybrid GAL10-PYK1 promoter (Dargevicuite et al, 2002). The plasmids were then 
transformed into Saccharomyces cerevisiae cells, strain FH4C and the yeast cells 
were incubated on a YEPD agar plate (1% yeast extract (Difco, Germany), 2% 
peptone, 2% glucose (Merck, Germany) and 5mM of formaldehyde (Carl Roth 
GmBH, Germany) for 24 hours at 30°C.  
Most of the colonies from the plate were then inoculated into fresh YEPD medium 
and incubated for 24 hours at 30°C on a shaker. The  induction medium, 75ml of 
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YEPD medium supplemented with 3% galactose (Carl Roth GmBH, Germany) and 
75µl formaldehyde was added to the yeast cells and the cells were then grown on a 
shaker for another 18 hours at 30°C.  
Yeast cells were harvested and washed with 10ml of 20mM pH 7.6 PBS (Biochrom, 
Germany) and centrifuged at 2000g for 20 minutes at 4°C. The supernatant was then 
discarded; the cell pellet was weighed and re-suspended in disruption buffer (50mL 
of 20mM, pH 7.6 PBS, 29g of 2mM EDTA (ICN Biomedicals GmbH, Germany) and 
500µl 1mM PMSF (Boehringer/Roche, Germany)). An equal volume of glass beads 
(Sigma, USA) was added and the cells were disrupted by vortexing for 10 minutes. 
The yeast lysate was then centrifuged at 10 000g for 40 minutes, supernatant 
discarded and the cell pellet was re-suspended in 10ml of extraction buffer (50mL of 
20mM, pH 7.6 PBS, 500µl of 1mM PMSF (Boehringer/Roche, Germany) and 1% 
Tween (Serva Electrophoresis, Germany)), shaken at 4°C for 30 minutes and 
centrifuged at 10 000g for 30 minutes in order to remove the contaminating proteins 
(Dargevicuite et al, 2002). The N protein-containing pellet was then re-suspended in 
10ml of re-suspension buffer (6M Guanidine-hydrochloride (ICN Biomedicals GmbH, 
Germany), 0.1M NaH2PO4 (Roth, Germany) and 0.01M Tris-Cl (Roth, Germany), pH 
8) and shaken at 200rpm and room temperature for 1 hour, and centrifuged for 20 
minutes at 10 000g and room temperature. Two millilitres of Ni2+-NTA agarose 
(Qiagen, Germany) was added to the re-suspended cells, the mixture was then 
added to a polypropylene column (Qiagen, Germany) and the column was washed 
with Qiagen buffers Buffer B (10ml), buffer C (20ml) and the protein washed with 
buffer D. The protein was then eluted 3× with 2ml of buffer E and collected in 2ml 
fractions.The purity of recombinant Puumala (PUU-rN) and Dobrava (DOB-rN) 
nucleocapsid proteins was determined on a 15% SDS-PAGE gel stained with 
Coomassie-blue. The specificity of the recombinant N protein was tested in Western 
blot assay using monoclonal antibodies: Puumala-specific (A1C5) and cross-reactive 
for Hantaan, Dobrava and Puumala virus (1C12 or E5G6). The bands observed on 
the Western Blot are for the PUU-rN-Vranica and DOB-rN-Slovakia with respective 
molecular weights of 50.3 kDa and 49.1 kDa. The purified N proteins were aliquoted 
and stored at 4°C until further use. 
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Before use in the assay antigens PUU-rN and DOB-rN were diluted in the coating 
buffer with a final concentration of 0.3µg/ml: the PUU-rN stock had a concentration of 
445µg/ml, 10µl of stock was added to 14823.3 µl coating buffer. The concentration of 
DOB-rN stock was 340µg/ml; 10µl of stock was mixed with 11323.3µl coating buffer. 
Working concentrations of both antigens were stored at 4°C. 
3.2.5  Preparation of ELISA Buffers 
Coating buffer was prepared by diluting 3.03g of Na2CO3 (Sigma Aldrich, Germany) 
and 6.0g of NaHCO3 (Sigma Aldrich, Germany) in water to make a 0.05 M 1L 
solution with pH 9.6. The pH of the solution was confirmed with the pH strips (Sigma 
Aldrich, USA). The Coating buffer can be stored for 2 weeks at room temperature. 
One gram of bovine serum albumin  (BSA) fraction V (Sigma Aldrich, Germany) was 
diluted in Dulbecco’s phosphate buffered saline (DPBS) without Ca2+ and Mg2+ 
(Biowhitaker, USA) to make 100ml 1% (m/v) BSA solution, which was stored at 4°C. 
The 3% (m/v) BSA Blocking buffer was prepared with 3g of BSA fraction V added to 
DPBS to make a 100 ml solution which was also stored at 4°C.  
For preparation of 10× wash buffer: a 1.0 M Tris-Cl was prepared by adding 12.11g 
of Tris ultrapure grade (Sigma Aldrich, Germany) to 80ml of distilled water. Seven 
millilitres of HCl (Sigma Aldrich, Germany) was added and then more water was 
added to make up a 100ml solution. The solution was then autoclaved at 121°C for 1 
hour. Ten millilitres of 1.0 M Tris-Cl, 17.56g of NaCl (Sigma Aldrich, Germany) and 
1ml of Tween® 20 (Sigma Aldrich, Israel) were added together and distilled water 
was added to make a 100ml solution. To make 1× wash buffer (working solution) 
50ml of 10× wash buffer was mixed with 450ml of water and the solution was stored 
at room temperature.  
Stop solution, 1.0 M H2SO4 was prepared by diluting 18M H2SO4 (Sigma Aldrich, 
Germany) in distilled water; 5ml of 18.0 M H2SO4 was slowly added to 85ml of water. 
The solution was stored at room temperature.  
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3.2.6  Positive and Negative Controls for ELISA 
The positive controls were obtained from the National Reference Laboratory for 
Hantaviruses at the Institut für Med. Virologie at Charité Universitätsmedizin in 
Berlin, Germany. Two IgG antibody positive control sera were used: H5 obtained 
from a patient infected with Dobrava (Slovakia) virus, H7 from a patient infected with 
Puumala virus. Both samples tested positive on the in-house IgG ELISA and results 
were confirmed by Western blot and Focus Reduction Neutralisation test (FRNT).  
Negative control sera were obtained from healthy donors with no history of an illness 
compatible with hantavirus disease in the Division of Medical Virology, Tygerberg, 
South Africa. Samples were tested for hantavirus-specific antibodies in duplicate 
using the ELISA assay; all the samples tested were negative and were subsequently 
used as negative controls in the assay. 
3.2.7  Screening of Patient Sera by ELISA 
Nunc® Polysorp 96-well microtitre plates (Nalgene, Denmark) were used. Two wells 
were allocated to each sample as well as the positive and negative controls. The first 
test well was coated with 100µl of antigen and the second control well was mock-
coated with the 100µl sample dilution buffer. Each plate was prepared according the 
template below (figure 3.2); the plate was divided in half, the first 6 columns were 
allocated for testing reactivity to DOB-rN and column 7 to 12 were allocated to PUU-
rN. 
 
 Figure 3.2 Template for the ELISA plates. 
1 2 3 4 5 6 7 8 9 10 11 12
Control Test Control Test Control Test Control Test Control Test Control Test
POS DOB POS DOB SAMPLE 8 SAMPLE 8 SAMPLE 16 SAMPLE 16 POS PUU POS PUU SAMPLE 8 SAMPLE 8 SAMPLE 16 SAMPLE 16
SAMPLE 1 SAMPLE 1 SAMPLE 9 SAMPLE 9 SAMPLE 17 SAMPLE 17 SAMPLE 1 SAMPLE 1 SAMPLE 9 SAMPLE 9 SAMPLE 17 SAMPLE 17
SAMPLE 2 SAMPLE 2 SAMPLE 10 SAMPLE 10 SAMPLE 18 SAMPLE 18 SAMPLE 2 SAMPLE 2 SAMPLE 10 SAMPLE 10 SAMPLE 18 SAMPLE 18
SAMPLE 3 SAMPLE 3 SAMPLE 11 SAMPLE 11 SAMPLE 19 SAMPLE 19 SAMPLE 3 SAMPLE 3 SAMPLE 11 SAMPLE 11 SAMPLE 19 SAMPLE 19
SAMPLE 4 SAMPLE 4 SAMPLE 12 SAMPLE 12 SAMPLE 20 SAMPLE 20 SAMPLE 4 SAMPLE 4 SAMPLE 12 SAMPLE 12 SAMPLE 20 SAMPLE 20
SAMPLE 5 SAMPLE 5 SAMPLE 13 SAMPLE 13 SAMPLE 21 SAMPLE 21 SAMPLE 5 SAMPLE 5 SAMPLE 13 SAMPLE 13 SAMPLE 21 SAMPLE 21
SAMPLE 6 SAMPLE 6 SAMPLE 14 SAMPLE 14 SAMPLE 22 SAMPLE 22 SAMPLE 6 SAMPLE 6 SAMPLE 14 SAMPLE 14 SAMPLE 22 SAMPLE 22
SAMPLE 7 SAMPLE 7 SAMPLE 15 SAMPLE 15 SAMPLE 23 SAMPLE 23 SAMPLE 7 SAMPLE 7 SAMPLE 15 SAMPLE 15 SAMPLE 23 SAMPLE 23
Control wells are coated with sample dilution buffer
Test wells are coated with recombinant N antigen (rN)
Wells coated with DOB-rN Wells coated with PUU-rN
36 
 
 
The plates were then incubated for 1 hour at 37°C i n the Nuaire NU-4850-E to 
facilitate binding of the antigen to the wells (NuAire Inc., USA). Thereafter the 
contents of the wells were discarded and the plate gently tapped against a paper 
towel to remove the remaining fluid. 150µl of the blocking buffer was then added to 
the wells in order to block any spaces in the wells were no antigen bonded, thus 
decreasing the occurrence of non-specific binding of antibodies in sera, and the 
plates were incubated at room temperature for 1 hour. Following incubation the 
blocking buffer was discarded in the same way as the coating and dilution buffer. 
The plates were then washed 4× with wash buffer was on the MultiWash II plate 
washer (Tricontinent, USA) to remove unbound blocking buffer and antigens.  
 
The patient sera and the controls were then diluted (1:200) in sample dilution buffer 
and 100µl of sera and negative control was added to the respective wells. The plates 
were then incubated for 1 hour at 37°C to facilitat e binding of any antibodies present 
in the sera to the antigen. After incubation the contents of the wells are discarded 
and 4× wash done to remove any antibodies that did not bind to the antigen.  
 
The goat anti-human IgG HRP-conjugated antibody (Promega, USA,) specific for 
both heavy and light chains on human antibodies was diluted in the sample dilution 
buffer with a final concentration of 0.4µg/ml and 100µl of the diluted antibody was 
added to all the wells whereupon the plate was incubated again for 1hour at 37°C. 
The HRP-conjugated antibody was added to bind to the human antibodies present.  
The contents of the wells were discarded and the 4× wash repeated, then 100µl of 
BDOpt® EIA TMB substrate was prepared according the instructions given by the 
manufacturer (BD Biosciences, USA) was added to the wells and then the plate was 
incubated for 20 minutes at room temperature in the dark. TMB substrate is a 
chromogenic substrate that produces a coloured product in the presence of HRP, 
resulting in the formation of blue colour in the positive wells. Then 100µl of stop 
solution a 1.0 M Sulphuric acid (Sigma Aldrich, Germany) was added to each well 
and colour change was observed in the reactive wells from blue to yellow. 
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The plate was read on the ELISA plate reader (Worldwide Diagnostics, USA) at 
450nm to measure optical density in each well, using air as the blank.  
For each test well, the optical density (OD) value for the control well was subtracted 
from the OD value for the test well to obtain the net OD of each sample to DOB-rN 
and PUU-rN: Test OD450 – Control OD450 = antibody activity (net OD450) 
Samples were considered positive if the value obtained was greater than or equal to 
0.150 (Klempa et al, 2010).  
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CHAPTER 4 
4 Results 
4.1 Animal Trapping  
A total of 576 rodent specimens were obtained for screening. Most of the animals 
were trapped at localities in the Western Cape, some in the Northern Cape and only 
one animal was strapped in Southern Namibia (Addendum C). The majority of the 
animals trapped were Rhabdomys pumilio. Table 4.1 below shows the distribution of 
the species that were trapped. 
 
Table 4.1 Rodents and shrews trapped for the study, 2007-2009. 
Species  Number of specimens 
Rhabdomys pumilio 513 
Gerbilluris paeba 9 
Rattus rattus 13 
Otomys unisulcatus 6 
Aethomys sp. 6 
Otomys irroratus 2 
Saccostomys sp 1 
Parotomys sp 1 
Mus musculus 6 
Shrews: Soricidae family 
(species not determined, classification based on 
physical features ) 6 
TOTAL 576 
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4.2 Hantavirus Screening 
The reverse-transcribed Dobrava virus cDNA was amplified and visualised on a 1% 
agarose gel. Ten-fold serial dilutions of the cDNA were prepared down to 100 000× 
dilution, amplified and visualised on a 1% gel.  
 
Figure 4.1 Pre-nested amplification product of the positive control. 
1% agarose gel picture of the pre-nested amplification product of the cDNA positive control. 
After the first round of amplification, the 1000× and 100× are clearly amplified. Faint bands of 
the 10 000× are visible as well. Size of the bands is ~412bp 
 
 
Figure 4.2 Nested amplification product of the positive control 
1% agarose gel picture of the nested amplification product of the cDNA positive control. After 
nested amplification the product of 10 000× is visualised on the gel. Size of band is ~390bp 
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When screening specimens for hantavirus RNA, the positive control was used at 10 
000× dilution. The objective was to use the lowest concentration of positive control at 
which strong amplification bands can be observed, to be economical with the control 
material without compromising the quality of the assay run, by ensuring that it has 
been efficient. 
 
RNA was extracted from the lungs of all 576 animals that were trapped. All the 
samples were screened by pre-nested and nested Pan-Hanta PCR. All assay runs 
were valid, with positive and negative controls showing the expected results. All 
specimens tested negative when the nested PCR product was visualised on 1% 
agarose gel. Several samples tested positive on the first run; to confirm these result, 
RNA was extracted again from the remaining tissue and amplified again by PCR. On 
repeat testing, all these samples tested negative, suggesting that the positive result 
observed initially was due to cross-contamination from the positive control well since 
the samples were amplified in 0.2ml 8-well PCR strips (Axygen, USA). 
4.3 Screening of Patient Sera by ELISA 
4.3.1 Patients with Acute, Suspected Hantavirus-related Disease 
No samples were received from patients with acute illnesses that might possibly 
hantavirus diseases were collected from hospital wards. 
4.3.2 Opportunistic (convenience) Serosurvey  
One hundred and sixty one residual sera samples were collected from the National 
health laboratory services (NHLS) at Tygerberg hospital tested for the presence of 
hantavirus specific antibodies; 99 of the specimens were from female patients and 
62 from male patients (Addendum D). All samples were anonymised, with only age 
and sex recorded from the hospital stickers on the blood tubes.  
Fourteen of the samples were obtained from males under the age of 30, 19 were 
from patients between age 30 and 50 years and 27 of the sera originated from 
patients over the ages of 50. Twenty-three of the specimens originated from female 
patients under 30 years of age, 37 from patients between age 30 and 50 years, and 
38 from female patients over the age of 50. Age could not be recorded for 1 
specimen from a male and from 2 female patients. 
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Table 4.2 Optical density OD450 values for the positive control sera. 
Dobrava (H5) 0.703 
Puumala (H7) 0.541 
 
Table 4.3 Results DOB-rN ELISA.  
Net optical density at 450nm for each sample is stated. The samples with OD450 ≥ to 0.150 
were considered positive. Positive results are highlighted in bold. 
Antibody activity  - Net OD450 DOB-rN 
Specimen 
number 
  
Specimen 
number 
  
Specimen number 
  
HAN – 1 0.034 HAN - 55 0.174 HAN - 109 0.072 
HAN – 2 0.094 HAN - 56 0.031 HAN - 110 0.053 
HAN – 3 0.007 HAN - 57 0.181 HAN - 111 0.061 
HAN – 4 0.045 HAN - 58 0.032 HAN - 112 0.045 
HAN – 5 -0.011 HAN - 59 0.057 HAN - 113 0.030 
HAN – 6 0.043 HAN - 60 0.074 HAN - 114 0.074 
HAN – 7 0.025 HAN - 61 0.023 HAN - 115 0.067 
HAN – 8 0.027 HAN - 62 0.132 HAN - 116 0.032 
HAN – 9 -0.002 HAN - 63 0.398 HAN - 117 0.085 
HAN – 10 0.042 HAN - 64 0.047 HAN - 118 0.040 
HAN – 11 0.041 HAN - 65 0.123 HAN - 119 0.033 
HAN – 12 0.029 HAN - 66 0.250 HAN - 120 0.047 
HAN - 13 -0.004 HAN - 67 0.060 HAN - 121 0.191 
HAN - 14 0.022 HAN - 68 0.118 HAN - 122 0.038 
HAN - 15 0.067 HAN - 69 0.069 HAN - 123 0.066 
HAN - 16 0.000 HAN - 70 0.016 HAN - 124 0.103 
HAN - 17 0.016 HAN - 71 0.099 HAN - 125 0.165 
HAN - 18 -0.001 HAN - 72 0.016 HAN - 126 0.074 
HAN - 19 -0.002 HAN - 73 0.014 HAN - 127 0.039 
HAN - 20 -0.002 HAN - 74 0.025 HAN - 128 0.036 
HAN - 21 0.013 HAN - 75 0.023 HAN - 129 0.041 
HAN - 22 0.017 HAN - 76 0.019 HAN - 130 0.056 
HAN - 23 0.009 HAN - 77 0.036 HAN - 131 -0.019 
HAN - 24 0.042 HAN - 78 0.023 HAN - 132 -0.024 
HAN - 25 0.082 HAN - 79 0.026 HAN - 133 -0.031 
HAN - 26 0.024 HAN - 80 0.036 HAN - 134 -0.010 
HAN - 27 0.058 HAN - 81 0.022 HAN - 135 0.002 
HAN - 28 0.013 HAN - 82 0.006 HAN - 136 -0.003 
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HAN - 29 -0.004 HAN - 83 0.032 HAN - 137 -0.073 
HAN - 30 -0.013 HAN - 84 0.078 HAN - 138 -0.012 
HAN - 31 0.192 HAN - 85 0.049 HAN - 139 -0.062 
HAN - 32 0.094 HAN - 86 0.214 HAN - 140 0.097 
HAN - 33 0.046 HAN - 87 0.064 HAN - 141 0.054 
HAN - 34 0.674 HAN - 88 0.085 HAN - 142 0.081 
HAN - 35 0.015 HAN - 89 0.024 HAN - 143 0.231 
HAN - 36 0.031 HAN - 90 0.011 HAN - 144 0.102 
HAN - 37 0.100 HAN - 91 0.168 HAN - 145 0.050 
HAN - 38 0.042 HAN - 92 0.079 HAN - 146 0.026 
HAN - 39 0.039 HAN - 93 0.019 HAN - 147 0.158 
HAN - 40 0.030 HAN - 94 0.029 HAN - 148 0.077 
HAN - 41 0.019 HAN - 95 0.016 HAN - 149 0.153 
HAN - 42 0.019 HAN - 96 0.049 HAN - 150 0.046 
HAN - 43 0.030 HAN - 97 0.147 HAN - 151 0.285 
HAN - 44 0.068 HAN - 98 0.068 HAN - 152 0.046 
HAN - 45 0.077 HAN - 99 0.017 HAN - 153 0.139 
HAN - 46 0.143 HAN - 100 0.007 HAN - 154 0.009 
HAN - 47 0.033 HAN - 101 0.266 HAN - 155 0.544 
HAN - 48 0.047 HAN - 102 0.047 HAN - 156 0.061 
HAN - 49 0.279 HAN - 103 0.016 HAN - 157 0.271 
HAN - 50 0.063 HAN - 104 0.033 HAN - 158 0.062 
HAN - 51 0.076 HAN - 105 0.043 HAN - 159 0.049 
HAN - 52 0.063 HAN - 106 0.090 HAN - 160 0.104 
HAN - 53 0.135 HAN - 107 0.190 HAN - 161 0.047 
HAN - 54 0.215 HAN - 108 -0.005     
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Table 4.4 Results PUU-rN ELISA.  
Net optical density at 450nm for each sample is stated. The cut-off for positive values is 
≥0.150 and positive results are highlighted in bold 
Antibody activity  - Net OD450 PUU-rN 
Specimen 
number 
 
Specimen number 
 
Specimen 
number 
  
HAN – 1 -0.036 HAN – 55 0.007 HAN – 109 0.069 
HAN – 2 0.013 HAN – 56 0.059 HAN – 110 0.074 
HAN – 3 0.028 HAN – 57 0.014 HAN – 111 0.093 
HAN – 4 0.005 HAN – 58 0.006 HAN – 112 0.036 
HAN – 5 0.002 HAN – 59 0.025 HAN – 113 0.115 
HAN – 6 -0.021 HAN – 60 0.005 HAN – 114 0.067 
HAN – 7 -0.031 HAN – 61 -0.007 HAN – 115 0.162 
HAN – 8 0.011 HAN – 62 0.023 HAN – 116 0.029 
HAN – 9 0.004 HAN – 63 0.050 HAN – 117 0.036 
HAN – 10 0.001 HAN – 64 -0.008 HAN – 118 0.021 
HAN – 11 0.023 HAN – 65 0.035 HAN – 119 0.084 
HAN – 12 -0.015 HAN – 66 0.044 HAN – 120 0.064 
HAN – 13 0.022 HAN – 67 0.001 HAN – 121 0.132 
HAN – 14 0.006 HAN – 68 0.005 HAN – 122 0.036 
HAN – 15 0.062 HAN – 69 0.012 HAN – 123 0.038 
HAN – 16 0.003 HAN – 70 0.013 HAN – 124 0.077 
HAN – 17 -0.018 HAN – 71 0.025 HAN – 125 0.129 
HAN – 18 -0.009 HAN – 72 0.162 HAN – 126 0.027 
HAN – 19 -0.005 HAN – 73 0.005 HAN – 127 0.046 
HAN – 20 0.007 HAN – 74 0.044 HAN – 128 0.034 
HAN – 21 0.001 HAN – 75 0.056 HAN – 129 0.051 
HAN – 22 0.031 HAN – 76 0.061 HAN – 130 0.046 
HAN – 23 -0.009 HAN – 77 0.065 HAN – 131 0.072 
HAN – 24 -0.003 HAN – 78 0.032 HAN – 132 0.072 
HAN – 25 -0.003 HAN – 79 0.026 HAN – 133 0.047 
HAN – 26 0.015 HAN – 80 0.043 HAN – 134 0.089 
HAN – 27 0.015 HAN – 81 0.009 HAN – 135 0.038 
HAN – 28 0.044 HAN – 82 0.021 HAN – 136 0.048 
HAN – 29 0.014 HAN – 83 0.029 HAN – 137 0.067 
HAN – 30 0.018 HAN – 84 0.504 HAN – 138 0.055 
HAN – 31 0.014 HAN – 85 0.025 HAN – 139 0.032 
HAN – 32 0.017 HAN – 86 0.092 HAN – 140 0.100 
HAN – 33 0.015 HAN – 87 0.103 HAN – 141 0.039 
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HAN – 34 0.006 HAN – 88 0.166 HAN – 142 0.081 
HAN – 35 0.033 HAN – 89 0.033 HAN – 143 0.106 
HAN – 36 0.013 HAN – 90 0.021 HAN – 144 0.072 
HAN – 37 0.038 HAN – 91 0.078 HAN – 145 0.031 
HAN – 38 0.004 HAN – 92 0.101 HAN – 146 0.025 
HAN – 39 0.013 HAN – 93 0.032 HAN – 147 0.154 
HAN – 40 0.018 HAN – 94 0.072 HAN – 148 0.05 
HAN – 41 0.107 HAN – 95 0.055 HAN – 149 0.073 
HAN – 42 0.008 HAN – 96 0.031 HAN – 150 0.049 
HAN – 43 0.010 HAN – 97 0.058 HAN – 151 0.247 
HAN – 44 0.024 HAN – 98 0.114 HAN – 152 0.072 
HAN – 45 0.005 HAN – 99 0.046 HAN – 153 0.115 
HAN – 46 0.011 HAN – 100 0.025 HAN – 154 0.048 
HAN – 47 0.005 HAN – 101 0.099 HAN – 155 0.041 
HAN – 48 0.002 HAN – 102 0.044 HAN – 156 0.057 
HAN – 49 0.011 HAN – 103 0.044 HAN – 157 0.203 
HAN – 50 0.003 HAN – 104 0.045 HAN – 158 0.056 
HAN – 51 0.006 HAN – 105 0.068 HAN – 159 0.052 
HAN – 52 0.011 HAN – 106 0.090 HAN – 160 0.048 
HAN – 53 0.003 HAN – 107 0.152 HAN – 161 0.043 
HAN – 54 0.006 HAN – 108 0.146     
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Table 4.5 Samples positive for DOB IgG antibodies, with details of the patient. 
Sera with antibodies reactive to DOB-rN 
Specimen 
number 
Net OD450  
DOB-rN Age Sex 
HAN – 31 0.192 33 M 
HAN – 34 0.674 51 M 
HAN – 49 0.279 76 F 
HAN – 54 0.215 48 F 
HAN – 55 0.174 30 F 
HAN – 63 0.398 39 F 
HAN – 66 0.250 52 M 
HAN – 86 0.214 65 M 
HAN – 91 0.168 50 M 
HAN – 101 0.266 45 M 
HAN – 107 0.190 34 M 
HAN – 121 0.191 38 F 
HAN – 143 0.231 59 M 
HAN – 147 0.158 37 F 
HAN – 149 0.153 49 M 
HAN – 151 0.285 68 M 
HAN – 155 0.544 13 M 
HAN – 157 0.271 49 F 
 
Table 4.6 Samples positive for PUU IgG antibodies, with details of the patient. 
Sera with antibodies reactive to PUU-rN 
Specimen 
number 
Net OD450 
PUU-rN Age Sex 
HAN – 72 0.162 27 F 
HAN – 84 0.504 54 F 
HAN – 88 0.166 45 F 
HAN – 107 0.152 34 M 
HAN – 115 0.162 28 F 
HAN – 147 0.154 37 F 
HAN – 151 0.247 68 M 
HAN – 157 0.203 49 F 
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Table 4.7 Percentages of reactive specimens for each antigen and for both antigens 
Antibody activity Females Males 
 
DOB-rN 7 11 18/161 (11.18%) 
PUU-rN 6 2 8/161 (4.97%) 
PUU-rN and DOB-rN 2 2 4/161 (2.48%) 
Total 13 13 26 
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CHAPTER 5 
5  Discussion 
5.1 History of Hantaviruses 
After the identification of Hantaan virus, the prototype of the genus, and identification 
of its host Apodemus agrarius coreae in 1978 by Lee et al, the search for hantavirus 
and respective reservoir hosts intensified. Hantaan virus has since been detected in 
Korea, China, Monogolia, as well as eastern Russia. Seoul and related hantaviruses 
have been identified in most of Asia, the Americas, and Europe and in 13 African 
countries since its hosts, members of the Rattus genus, are found on every continent 
with the exception of Antarctica (Lee, 1996). In Europe, Puumala and Dobrava 
hantaviruses were identified during the 1980s and 1990s, respectively (Harper & 
Meyer, 1999). 
The Thottapalayam virus (TPMV) was first isolated in India in 1964 from Suncus 
murinus (Asian House Shrew) and was initially classified as an arbovirus. However 
subsequent studies showed that TPMV has bunyavirus morphology and the 
conserved terminal panhandle nucleotide signature carried by all known 
hantaviruses (Maes et al, 2007). It was the first hantavirus isolated from a non-rodent 
host. Since then numerous shrew-borne hantaviruses have been identified in Asia, 
Europe, North and South America such as the Asama virus (Urotrichus talpoides), 
American Ash river virus and Jemez Springs virus in the Masked Shrew (Sorex 
cinereus) and Dusky Shrew (Sorex monticolus), Cao Bang virus in Chinese shrew 
mole (Song et al, 2007b) and Seewis virus in the Eurasian common shrew (Sorex 
araneus) (Song et al, 2007c).  
The prospect hill virus which is non-pathogenic was the first American hantavirus to 
be identified in Microtus pennylvanicus and Peromyscus leucopus (Lee et al, 1982). 
The outbreak of hantavirus cardiopulmonary syndrome (HCPS) in the Four Corners 
region, USA led to the identification of its causative agent the Sin Nombre virus and 
its host Peromyscus maniculatus (Harper & Meyer, 1999). Various other North 
American viruses and hosts were identified in other parts of the USA and Canada as 
well. The first South American HCPS cases were reported in Brazil in 1994, and the 
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only cases of human-to-human transmission of hantavirus infection was observed 
during the Andes virus outbreak in Argentina in 1996 (Martinez et al, 2005).  
There are approximately 150 000 cases of Haemorrhagic fever with renal syndrome 
(HFRS) reported worldwide every year, most of them in China and  several thousand 
cases of Nephropathia epidemica (NE)  are reported in Europe annually (Sjölander & 
Lundkvist, 1999) while approximately 2500 cases of hantavirus cardiopulmonary 
syndrome (HCPS) have been reported so far in the Americas (Vaheri et al, 2008). 
Hantaviruses have rarely been investigated outside the regions where clinical 
disease is frequently observed despite their potential importance as human 
pathogens. A comparison of the geographic distribution of Muridae rodents and the 
associated hantavirus demonstrates that the currently known distribution of 
hantaviruses does not match the distribution of rodent hosts. Further rodent studies 
are therefore necessary, especially in Africa and South Asia in order to better 
understand the distribution of hantaviruses (Hettonen et al, 2008). 
5.2 Evidence for Hantaviruses in Africa 
The most recent serology study in Africa was a population-based survey carried out 
in Guinea, where the first African hantaviruses were identified. Seven hundred and 
seventeen samples were tested; 68 were from patients from Sangassou village and 
649 were residual samples from a Lassa fever study performed in 2001. The patient 
sera were tested for the presence of IgG antibodies against Puumala, Dobrava and 
Sangassou viruses by ELISA using recombinant N proteins of the above mentioned 
viruses and results were confirmed by IFA and focus reduction neutralisation test 
(FRNT). ELISA was also employed to test for the presence of IgM antibodies.  
Results of the survey showed a 1.2% prevalence of hantavirus antibodies (Klempa et 
al, 2010).  
No disease has been associated with SANGV and TGNV or any other African 
hantavirus, however the potential of these viruses and other unidentified 
hantaviruses to cause disease in humans cannot be ignored as it is possible that 
HFRS may be confused with other diseases such as other viral haemorrhagic fevers, 
rickettsiosis, plague, severe pneumonia and leptospirosis (Bi et al, 2008).  
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Previous surveys were done in the 1980s in Central and West African countries; 
Gonzalez et al conducted a survey in Cameroun, Central African Republic, Chad, 
Congo, Equatorial Guinea and Gabon; 2893 samples were collected randomly in 
1985-87, and tested by IFA for the presence of hantavirus specific antibodies. The 
survey reported a prevalence of 6.15% (Gonzalez et al, 1989). A previous survey 
has been conducted in the Central African Republic between 1982 and 84 and 
reported 0.7% prevalence (Gonzalez et al, 1988). Studies were also conducted in 
Senegal (Saluzzo et al, 1985), Nigeria (Tomori et al, 1986) and Egypt (Bostros et al, 
2004) has found evidence of hantavirus infection in humans. Two studies were 
conducted in Egypt the first conducted by Hoogstraal et al reported seroprevalence 
of 0-6% in adults and  the Corwin  et al study reported a prevalence of 9% in children 
(Corwin et al, 1992). Studies in Asia have found the hantavirus antibody prevalence 
varies from 0.48% in Japan and 33% in Thailand. In Europe seroprevalence is as 
low as 0-1.9% in Switzerland and as high as 24% in Puumala virus endemic areas in 
Norway. Prevalence in America is as high as 43% in the Chaco area in Panama 
where HCPS is endemic (Bi et al, 2008).  
The first African hantavirus, Sangassou virus (SANGV), was identified in 2006; 1129 
blood specimens from Guinea west Africa were screened using the degenerate pan-
hanta primers targeting a conserved region on the L-segment of the viral genome 
(Klempa et al, 2006). Phylogenetic studies of the nucleotide and amino acid 
sequences of all three viral segments showed that the virus is most closely related to 
Dobrava virus (figure 5.1) (Klempa et al, 2006; Hettonen et al, 2008).   
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Figure 5.1 Maximum likelihood phylogenetic tree of some of the hantaviruses constructed 
using partial S segment sequences [Source: Klempa et al, 2006]. 
5.3 The Search for a Novel Southern African Hantavirus 
In this study 576 animals were trapped, most of which are Rhabdomys pumilio which 
is the target species for the parasite study currently being conducted by Sonja 
Matthee. Trapping was focussed in limited localities; mostly in the Western Cape and 
some trapping was done in the Northern Cape and southern Namibia and only 6 
different species were trapped in our study. In the Guinea study which resulted in the 
idenitifcation of the first two African hantaviruses, specimens from 17 different 
species were tested for the presence of hantaviruses. Another limitation is the lack of 
a positive control to be extracted and reverse-transcribed simultaneously with the 
specimens; a cDNA control was run with the reverse-transcribed RNA samples 
during the pre-nested and nested amplification. 
Sero-epidemiologic survey was carried out by Lee et al (1999) in South Africa; 
rodent sera were collected from various rodent species trapped in the Northern Cape 
and Western Cape provinces. Hantavirus antibodies were detected in 2 of the 221 
rodents, Aethomys namaquensis and Tatera leucogaster (Lee et al, 1999). In our 
study, only 6 Aethomys sp. were screened for the presence of hantavirus sequences 
and all tested negative.  
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Identification of a positive specimen would have resulted in subsequent sequencing 
and comparison of the obtained sequence to known members of the genus to 
determine, sequence similarity on a nucleotide and amino acid level by comparing S-
, M- and L –segments to determine if a new species has been identified according 
the criteria set out by the ICTV. Rodent or shrew trapping would then be conducted 
in the area from which the positive animal was trapped previously in order to 
determine prevalence of infection in the local population by RT-PCR. A recombinant 
antigen would be prepared of the new virus and used to set up an in-house 
serological assay, an ELISA. 
An attempt would also have been made to isolate the novel virus from cultures, using 
Vero E6 cells. Successful virus isolation of the virus would allow, focus reduction 
neutralisation test (FRNT) based in the novel virus; it is the gold standard for 
serotyping hantaviruses. Sera from human beings near the trapping area would be 
tested to determine of the virus is the cause of human infections in specimens that 
test positive in ELISA and western Blot assays. 
A sero-survey of the general population in the area or near the area the positive 
animal was tested would be conducted to determine the prevalence of hantavirus 
specific antibodies using the in-house with recombinant antigen based on the novel 
virus). This is the same approach that was followed Guinea following the 
identification of SANGV and TGNV; 68 serum samples were screened from 
residents with fever of unknown origin in Sangassou village retrospectively and IgG 
antibodies were detected in 3 of them. One of the positive subjects (S55) exhibited 
HFRS-like disease for 1 week and suffered from chills, headache, asthenia, myalgia, 
breathing difficulty, nausea, vomiting, oliguria, hypotonia, and oedema of the face 
and lower extremities (Klempa et al, 2010).  
Serum taken from the S55 during the acute phase of illness tested positive for IgM 
antibodies (Table 5.1). The two other seropositive patients also had HFRS-like 
disease but it was less severe (Klempa et al, 2010). Below is a table showing the 
test results from patient S55. 
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Table 5.1 ELISA results from S55.  
Post acute and post covalescent serum from the subject was tested [Source: Klempa et al, 
2010]. 
 
Though no novel hantavirus was isolated in this study, trapping will continue. 
Strategies will have to be put in place to improve the chances of identifying a 
Southern African hantavirus. Various research groups targeted rodents and shrews 
closely related to known reservoir hosts of hantaviruses. Arai et al identified a novel 
hantavirus in testing stored tissue from the northern short-tailed shrew (Blarina 
brevicauda) in the USA. The Imjin virus was identified in the Ussuri white-toothed 
shrew (Crocidura lasiura) closely related to TPMV host Suncus murinus (Song et al, 
2009).  
In southern Africa, 4 Suncus species occur and there are more than 103 Crocidura 
species, which occur in most of Africa with the exception certain parts of the Sahara. 
Crocidura species are the most common and most diverse shrew in Africa. They 
occur in all vegetation types and at all altitudes (Kingdon, 2003). 
Another strategy would be target the species that tested positive in the 
seroepidemiologic study conducted in the late 1990s in South Africa (Lee et al, 
1999), Aethomys namaquensis and Tatera leucogaster as well as to expand trapping 
into other ecosystems in South Africa, which should increase the variety of rodents 
and shrews being trapped. In the next phase of our study, more rodent trapping will 
be conducted in the coming  spring and early summer. Plans are underway for 
trapping in Namibia to moving northwards into forest and woodland savannah as 
well.  
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5.4 Detection of Hantavirus-specific Antibodies in the South African 
Population 
The diagnosis of HFRS and HCPS in human beings relies predominantly on 
serological testing. PCR has been used successfully in detecting PUU RNA in some 
patient specimens, but the short duration or absence of viraemia during the acute 
phase of infection means that other methods must be used for patient diagnosis 
(Sjölander & Lundkvist, 1999). Immunofluorescence assays (IFA) have been the 
traditional method of hantavirus serological diagnosis but it is less sensitive when 
compared to N protein-based ELISAs (Sjölander & Lundkvist, 1999; Meisel et al, 
2006).  The nucleocapsid protein is highly immunogenic in reservoir hosts, 
immunised laboratory animals as well as infected humans (Meisel et al, 2006). Viral 
antigens from hantavirus infected cells or recombinant N proteins are used in 
serological assays; recombinant N proteins (rN) are used in assays because N-
specific antibodies occur early after infection and probably persist for life, the N 
protein can be expressed in E.coli, yeast and insect cells. The high level of 
conservation of the N protein among members of the genus means that cross-
reaction between distantly related hantaviruses occurs; this allows for the detection 
of a majority of hantavirus infections by heterologous antigen but compromises a 
species-specific diagnosis should it be required, e.g. in areas where more than one 
hantavirus occurs and may cause diseases with different severity (Elgh et al, 1998; 
Sjölander & Lundkvist, 1999; Meisel et al, 2006).  
In the in-house ELISA assay set up in our study, recombinant N antigens PUU-rN 
and DOB-rN prepared in yeast cells were used to detect anti-hantavirus IgG 
antibodies in patient sera collected in the Western Cape in a opportunistic 
serosurvey;161 residual serum (clotted blood) samples from human patients sent for 
routine laboratory testing at the NHLS laboratories in Tygerberg Hospital that are left 
over after the requested tests have been done and would otherwise be discarded. 
Samples were tested against PUU-rN and DOB-rN and positive results were 
observed in 26 of the samples; 18 samples were reactive against DOB-rN, 8 were 
reactive against PUU-rN and 4 were reactive against both antigens. 
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Non-specific binding can result in false positives; it is therefore possible that some 
specimens especially those with OD450 values equal to or close to 0.150 are false 
positives. Positive results on the on the ELISA assay will therefore be confirmed by 
Immunoblot assay and focus reduction neutralisation test (FRNT), although FRNT 
can only be performed once an indigenous virus is isolated from cell culture.  
A sero-epidemiologic survey was conducted in South Africa in the late 1990s to 
determine the presence of hantavirus serologically. In this survey, sera were 
collected from patients with renal failure, pulmonary syndrome, and fever of unknown 
origin admitted to hospitals in Cape Town. Sera were also collected in the general 
population in the Eastern Cape and Western Cape provinces (Lee et al, 1999).  
Sera were screened for hantavirus specific antibodies by immunofluorescence assay 
(IFA) using Hantaan, Seoul, Puumala, and Prospect Hill viruses. Sera positive in the 
IFA test then confirmed by a differential IFA test and plaque reduction neutralisation 
assay (PRNT). A prevalence of 0.57% was observed in the Eastern Cape and 2% 
prevalence was observed in the Western Cape. Of the sera from the recruited 
patients, 3 of the 318 patients diagnosed with chronic renal failure, acute respiratory 
distress syndrome and glomerulonephritis tested positive (Lee et al, 1999). 
In the next phase of our study, the sera that tested positive on the IgG ELISA will be 
tested using more specific serological assays such as immunofluorescence assay 
(IFA) as well as the Western blot. This confirmatory testing is necessary as the 
screening ELISAs are known to produce a substantial rate of non-specifically 
reactive specimens (Chandy et al, 2009). 
The recruitment of acutely ill patients with hantavirus-like disease fever of unknown 
origin, not responding to antibiotic treatment, along with any of the following of 
unknown aetiology: acute renal failure, acute respiratory failure, acute liver failure, 
pneumonia and/or mucosal bleeding will also commence. Information about signs 
and symptoms exhibited in the patients as well as possible location of exposure for 
the patients will be recorded (Addendum B).   
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Patients will be recruited at tertiary hospitals in Cape Town: Tygerberg hospital and 
Groote Schuur hospital with the assistance of physicians in the renal and respiratory 
care units at the respective hospitals. These specimens will be tested for IgG and 
IgM antibodies by ELISA using and any positive results will be confirmed by 
immunoblot assay and FRNT. Studying these patients will lead to the formation of a 
clinical case definition for hantavirus disease in South Africa.  
 
56 
 
Conclusion  
In this study, an attempt was made to identify and isolate the first Southern African 
hantavirus. A total of 576 lung specimens from a variety of rodents and shrews 
trapped in the Western Cape, Northern Cape and southern Namibia where screened 
for the presence of hantavirus sequences using universal Pan-Hantavirus 
degenerate primers designed to detect all known and unknown hantaviruses. All 
specimens tested were negative for hantaviruses. However, the inability to identify a 
novel hantavirus does not mean that no hantaviruses are present in South Africa; the 
sample size is still relatively small, and it may have missed the geographical area 
and / or host species implicated. Of note, Lee et al (1999) reported on the presence 
of hantavirus-specific antibodies in two individuals from South African rodent 
species, A. namaquensis and T. leucogaster by Immunofluorescence test using a 
panel of antigens from HTNV, PUUV and PHV respectively. Ours is the first known 
study to attempt the identification and isolation of hantaviruses in South Africa and 
Namibia.  
In addition, a convenience serosurvey was also conducted; residual serum samples 
from NHLS laboratories at Tygerberg hospital were tested for the presence of 
hantavirus-specific IgG antibodies using an in-house ELISA based on recombinant 
hantavirus N antigens from two European hantaviruses, DOBV and PUUV. Of 161 
human serum specimens tested, 11.2% were reactive against DOB-rN and 5.0% 
against PUU-rN, with 2.5% reactive against both recombinant antigens. These 
results from the ELISAs need to be confirmed by Western blot followed by serotyping 
by FRNT; however an indigenous virus will first have to be identified and isolated on 
cell culture before the latter can be attempted. Our study is the second known study 
conducted in South Africa to determine seroprevalence of hantavirus specific 
antibodies in the human population in the Western Cape and in South Africa. Lee et 
al (1999) found evidence of hantavirus in the general population as well as in 
patients hospitalised for acute renal failure, pulmonary oedema and 
glomerulonephritis.  
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In order to obtain a more representative and accurate picture of hantavirus 
seroprevalence in the human population, at least 1000 residual sera will be collected 
from laboratories in the Western Cape region in the next phase of the study and 
screened by ELISA; positive results will confirmed with the more specific immunoblot 
assay.  
It is important to conduct studies to investigate the occurrence of hantaviruses, even 
though no clinical case has been reported in South Africa, because it is through 
these studies that rodent populations can be surveyed so that society is equipped to 
respond more rapidly and diagnose accurately in the event of an outbreak. There is 
a possibility that hantavirus disease is occurring in southern Africa but is incorrectly 
diagnosed as either another viral haemorrhagic fever, leptospirosis, disease caused 
by a rodent-borne bacteria Leptospira sp. (Levett, 2001) or rickettsiosis caused by 
Rickettsia africae which is a tick-borne bacterium (Olano & Walker, 2009). The lack 
of state-of-the-art medical facilities and a case definition in South Africa and 
elsewhere on the continent may also contribute to the inability to diagnose 
hantavirus disease correctly in patients.  
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A. Information and consent form for the recruitment of patients 
Research project: Do hantaviruses occur in Southern Africa? 
Hantaviruses are members of the Bunyaviridae family. Their natural hosts are rodents 
and shrews. So far, more than 30 different hantavirus species have been found infecting 
different species of rodent or shrew.  
Some types of hantaviruses may cause 
zoonotic disease in human beings. 
Humans are typically infected by inhaling 
aerosolized excreta of infected rodents, 
e.g. when cleaning rodent-infested 
buildings. The two recognised hantavirus-
associated human disease entities are 
haemorrhagic fever with renal syndrome 
(HFRS) and hantavirus cardiopulmonary syndrome (HCPS). 
Until recently hantaviruses were known to occur in Asia, Europe 
and the Americas. However, in 2006 the first African hantavirus 
was identified in and isolated from the African wood mouse 
(Hylomyscus simus) in Guinea, West Africa. The new virus was 
named Sangassou, after the area where it was first detected. 
Soon afterwards genetic evidence for another hantavirus was 
detected in a Therese’s shrew (Crocidura theresae), also in West 
Africa, and named Tanganya virus.  
The identification of these two African hantaviruses has highlighted the possibility that there may be yet other 
hantaviruses in Africa that are yet to be identified. These viruses might infect and cause disease in human 
beings. It is possible that infections and diseases caused by yet unknown hantaviruses may be confused with 
other severe diseases such as rickettsiosis, severe pneumonia, leptospirosis, viral haemorrhagic fevers etc. 
Without specific laboratory testing, a hantavirus aetiology may not be recognised (as was the case with HFRS 
in Eurasia and HCPS in America before the responsible viruses were discovered). 
Our study aims to identify hantaviruses and possible hantavirus diseases in southern Africa. So far, the 
occurrence of these viruses and any possibly related illnesses is not known from our region. The study has been 
approved by the ethics committee of the University of Stellenbosch. We would like to test patients with 
clinical disease that might possibly be due to hantavirus infection, to see whether hantavirus infections do 
occur at all and if so, whether they may be causing disease. If we find evidence of hantavirus infection in 
patients a clinical case definition and diagnostic assays can be developed to help diagnose future cases. 
We are looking for patients with clinical symptoms that might be indicative of hantavirus disease. These 
symptoms are: 
• Fever of unknown origin, not responding to antibiotic treatment, 
PLUS 
• any of the following, of unknown aetiology: acute renal failure, acute respiratory failure, acute liver 
failure, pneumonia and/or mucosal bleeding. 
We need serum samples from patients fulfilling this case definition. The samples will be tested for the 
presence of hantavirus antibodies by an in-house ELISA assay. A patient information sheet and consent form 
have been developed and approved. A study sample form (asking for a minimum set of clinical information) is 
also available. 
For more information on the project please contact: 
Miss Ndapewa Ithete  Prof Wolfgang Preiser 
Division of Medical Virology Division of Medical Virology 
021 938 9360 021 938 9353 
14567008@sun.ac.za preiser@sun.ac.za 
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PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
TITLE OF THE RESEARCH PROJECT:  MOLECULAR IDENTIFICATION AND 
CHARACTERISATION OF RODENT- AND SHREW-BORNE HANTAVURSES 
REFERENCE NUMBER: N02/09/058 
PRINCIPAL INVESTIGATOR:    Ndapewa Ithete 
ADDRESS:    Division of Medical Virology, Department of Pathology, Faculty of Health 
Sciences, Stellenbosch University. 
CONTACT NUMBER:    021 938 9360 
You are being invited to take part in a research project. Please take some time to read the information 
presented here, which will explain the details of this project. Please ask the study staff or doctor any 
questions about any part of this project that you do not fully understand. It is very important that you 
are fully satisfied that you clearly understand what this research entails and how you could be 
involved. Also, your participation is entirely voluntary and you are free to decline to participate. If you 
say no, this will not affect you negatively in any way whatsoever. You are also free to withdraw from 
the study at any point, even if you do agree to take part. 
This study has been approved by the Committee for Human Research at Stellenbosch University 
and will be conducted according to the ethical guidelines and principles of the international 
Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the Medical Research 
Council (MRC) Ethical Guidelines for Research. 
What is this research study all about? 
This study aims to identify hantaviruses and hantavirus diseases in southern Africa. So far, the 
occurrence of these viruses and any possibly related illnesses is not known from our region. The idea 
is to test patients with clinical disease that might possibly be due to hantavirus infection for the 
evidence of this, to see whether hantavirus infections do occur at all and if so, whether they may be 
causing disease. 
Patients will be recruited at two hospitals: Tygerberg Hospital and Groote Schuur Hospital in Cape 
Town. 
Blood samples from patients with clinical symptoms that might be indicative of hantavirus disease will 
be collected. Such symptoms include fever of unknown origin not responding to antibiotic treatment, 
plus any of the following: acute renal failure, acute respiratory failure, and acute liver failure, mucosal 
bleeding, all of unknown aetiology. Blood samples will be obtained at different time points after onset 
of disease, frozen and later tested for hantaviruses. In addition, if and when biopsies (e.g. renal 
biopsies in cases of acute renal failure) are performed for routine diagnostic purposes, residual 
sample material will also be obtained for hantavirus testing. 
The aim of this project is to identify and characterise novel hantaviruses in patients whose clinical 
illness matches that seen in patients with proven hantavirus infection in other parts of the world. 
Patients will be selected based on clinical criteria and patient samples will be tested by molecular and 
serological methods. If we find evidence of hantavirus infection in such patients this will help us to 
define a clinical case definition and to develop diagnostic assays that might in future help to diagnose 
hantavirus-infected patients. 
When routine blood samples are taken from the participating patients, another (extra) tube of blood 
will be collected for the purposes of this study. This specimen will then be tested for the presence of 
anti-hantavirus antibodies and of hantavirus genome. 
Why have you been invited to participate? 
You have been chosen to participate because you are currently suffering from a disease which 
resembles that caused by hantaviruses in other parts of the world.  
What will your responsibilities be? 
To provide us with an extra blood sample when blood is taken for routine purposes anyway. One tube 
with 10 ml (2 to 3 teaspoons) of blood will be collected. 
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Will you benefit from taking part in this research? 
You will not benefit from this research directly yourself. Your participation would however be very 
valuable as it might lead to the identification of new viruses. This contributes to medical knowledge in 
general and will allow us to develop a clinical case definition of hantavirus disease in South Africa. 
Possible identification of hantaviruses will allow the development of diagnostic assays to be used to 
determine whether future patients have hantavirus infection.  
Are there in risks involved in your taking part in this research? 
There is minimal risk involved in your participation in this study as the extra blood specimen to be 
taken will be obtained at the same time as one or more for routine diagnostic testing (no extra needle 
prick involved). 
If you do not agree to take part, what alternatives do you have? 
Whether you wish to take part in this study or not will not affect your clinical care in any way. 
Who will have access to your medical records? 
All personal information collected will be treated as confidential and access to it will be strictly 
controlled and limited to the investigators. All identifying information will be anonymised at the earliest 
possible time point. All patient specimens will be assigned numbers for identification purposes when 
used in a publication or thesis. 
What will happen in the unlikely event of some form injury occurring as a direct result of your 
taking part in this research study? 
This is not applicable, as the only inconvenience is drawing an extra tube of blood from you at the 
same time as samples are being obtained for routine purposes anyway.  
Will you be paid to take part in this study and are there any costs involved? 
You will not be paid to take part in the study, and you will not incur any costs either. 
 
 
 
Is there any thing else that you should know or do? 
 You can contact Ms Ndapewa Ithete at telephone 021 938 9360 if you have any further 
queries or encounter any problems. 
 You can contact the Committee for Human Research at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your study doctor. 
 You will receive a copy of this information and consent form for your own records. 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research study 
entitled Molecular Identification and Characterisation of Rodent- and Shrew-borne 
Hantaviruses. 
 
I declare that: 
 
• I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been pressurised 
to take part. 
• I may choose to leave the study at any time and will not be penalised or prejudiced in 
any way. 
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• I may be asked to leave the study before it has finished, if the study doctor or researcher 
feels it is in my best interests, or if I do not follow the study plan, as agreed to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2010. 
 
 
 
 ............................................................................  .........................................................................  
Signature of participant Signature of witness 
 
 
5.4.1 Declaration by investigator 
I (name) ……………………………………………..……… declare that: 
 
• I explained the information in this document to ………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
• I did/did not use a interpreter.  (If a interpreter is used then the interpreter must sign the 
declaration below. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2010. 
 
 
 
 ............................................................................  .........................................................................  
Signature of investigator Signature of witness 
 
 
5.5 Declaration by interpreter (if applicable) 
 
I (name) ……………………………………………..……… declare that: 
 
• I assisted the investigator (name) ……..............…………………………………. to explain 
the information in this document to (name of participant) 
........................……………..…………………………….. using the language medium of 
Afrikaans/Xhosa (delete as applicable). 
• We encouraged him/her to ask questions and took adequate time to answer them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the participant fully understands the content of this informed consent 
document and has had all his/her question satisfactorily answered. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2010 
 
 
 ............................................................................  .........................................................................  
Signature of interpreter Signature of witness 
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B. Information pamphlet for the anonymous serosurvey 
Anonymous serosurvey: Do human hantavirus infections occur in South Africa? 
Aim: 
• This unlinked anonymous serosurvey aims to identify the occurrence of 
hantaviruses infecting human beings in southern Africa. 
Design: 
• Convenience collection ("opportunistic" samples): using residual serum (clotted 
blood) samples from human patients sent for routine laboratory testing that are 
left over after the requested tests have been done and would otherwise be 
discarded. 
• Serum samples originating from NHLS laboratories situated in rural areas of the 
Western Cape or receiving referrals from such areas. 
• Samples are anonymised upon receipt; only information on date of collection, age, 
sex and source laboratory is retained but no demographic or medical information 
on the patient. 
• Ethics approval will be sought from the Health Research Ethics Committee of the 
Faculty of Health Sciences, University of Stellenbosch. 
What we are looking for: 
• Colleagues from NHLS laboratories in the Western Cape who are willing to 
participate by sending us residual (left-over) serum samples that would otherwise 
be discarded. 
• Important: Only serum samples are required (blood containing additives such as 
EDTA or heparin will not be suitable for the serological methods to be used). 
• The samples should have been obtained and handled according to standard clinical 
and laboratory practices and stored in a refrigerator (at approximately +4°C). 
• Residual samples should be at least 0.3 ml. 
• In some other countries the average seroprevalence is around 1%. Based on this, 
between 1500 and 3000 specimens (but not all necessarily from the same area) 
would be desirable whilst still being a practicable quantity. 
• Upon receipt at Tygerberg, the remaining serum will be transferred into a new vial 
by the research team. If patient identifiers are present on the sample tube, only 
age and sex will be recorded and all original sample tubes will be discarded after 
the serum has been transferred. 
• Sera will be tested for the presence of hantavirus-specific antibodies by means of a 
cascade of antibody tests, starting with screening assays likely to yield a high 
number of non-specific reactive results which are then confirmed by using more 
specific assays such as microneutralisation. 
Rationale: 
• This approach is similar to (but more focussed and with a smaller geographical 
coverage than) that used in the United Kingdom for the Health Protection Agency’s 
(HPA) Seroepidemiology Programme (cf. http://www.hpa.org.uk/ProductsServices/ 
InfectiousDiseases/ServicesActivities/SeroepidemiologyProgramme): "Sera used are 
residues of specimens submitted for diagnostic testing, … are anonymised 
(retaining age, sex, date of collection and source laboratory only). Collection of 
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sera is continuing through collaboration with … laboratories throughout England 
and Wales." 
• Like the HPA Seroepidemiology Programme, this study "is focused on cross-sectional 
antibody prevalence … to help in the understanding of the epidemiology and 
burden of infectious diseases of public health importance, and how this may be 
changing. This provides key evidence to assist with making informed decisions 
regarding health policy where intervention is possible." A recent example of a 
research study in which this resource was used is Miller et al., Incidence of 2009 
pandemic influenza A H1N1 infection in England: a cross-sectional serological 
study. Lancet. 2010 Mar 27;375(9720):1100-8. 
Limitations: 
• Limited information will be collected on patient demographics (including 
occupation, location of possible exposure) or medical condition. 
• Given that the samples will originate from patients who have laboratory tests done 
within the public health sector, and given that such testing in South Africa is done 
less easily and less frequently than in most developed countries, the collection is 
likely to compromise predominantly patients with clinical illness and may therefore 
overestimate true population prevalence rates. 
• However the purpose of this anonymous serosurvey is to ascertain whether 
hantavirus-specific antibodies occur at all in human populations in the Western 
Cape, as a marker of past exposure to hantaviruses, and not to link hantavirus 
infection and possible hantavirus disease (this is addressed in a separate, ongoing 
study at Groote Schuur and Tygerberg hospitals, aiming to test patients with acute 
clinical disease that might possibly be due to hantavirus infection). 
For more information on the project please contact: 
Miss Ndapewa Ithete  Prof Wolfgang Preiser 
021 938 9360 021 938 9353 
14567008@sun.ac.za preiser@sun.ac.za 
Division of Medical Virology, Faculty of Health Sciences, Tygerberg 
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Addendum C 
 
Rodent and shrew trapping locations 
  
Beaufort West 
 
close to human dwellings 
 
 
Rhabdomys pumilio 
BwRp 1  
BwRp 2 
 
BwRp 3 
 
BwRp 4 
 
BwRp 5 
 
BwRp 6 
 
BwRp 7 
 
BwRp 8 
 
BwRp 9 
 
BwRp 10 
 
BwRp 11 
 
BwRp 12 
 
BwRp 13 
 
BwRp 14 
 
BwRp 15 
 
BwRp 16 
 
BwRp 17 
 
BwRp 20 
 
BwRp 21 
 
BwRp 22 
 
BwRp 23 
 
BwRp 24 
 
BwRp 25 
 
BwRp 26 
 
BwRp 27 
 
BwRp 28 
 
BwRp 29 
 
BwRp 30 
 
BwRp 31 
 
BwRp 32 
 
BwRp 33 
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Elandskloof 
  
Farm 
  
 
  
Rhabdomys pumilio 
 
EkRp 1 
  
EkRp 2 
  
EkRp 3 
  
EkRp 4 
  
EkRp 5 
  
EkRp 6 
  
EkRp 7 
  
EkRp 8 
  
EkRp 9 
  
EkRp 10 
  
EkRp 11 
  
EkRp 12 
  
EkRp 13 
  
EkRp 14 
  
EkRp 15 
  
EkRp 16 
  
EkRp 17 
  
EkRp 18 
  
EkRp 19 
  
EkRp 20 
  
EkRp 21 
  
EkRp 22 
  
EkRp 23 
  
EkRp 24 
  
EkRp 25 
  
EkRp 26 
  
EkRp 27 
  
EkRp 28 
  
EkRp 29 
  
EkRp 30 
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Goegap, Springbok   
  
old sheep farm   
  
    
  
Rhabdomys pumilio 
 
  
GpRp M 1 GpRp M 22 GpRp O 19 GpRp A 12 
GpRp M 2 GpRp M 23 GpRp O 20 GpRp A 13 
GpRp M 3 GpRp M 24 GpRp O 21 GpRp A 14 
GpRp M 4 GpRp M 25 GpRp O 22 GpRp A 15 
GpRp M 5 GpRp M 26 GpRp O 23 GpRp A 16 
GpRp M 6 GpRp M 27 GpRp O 24 GpRp A 17 
GpRp M 7 GpRp M 28 GpRp O 25 GpRp A 18 
GpRp M 8 GpRp M 29 GpRp O 26 GpRp A 19 
GpRp M 9 GpRp M 30 GpRp O 27 GpRp A 20 
GpRp M 10 GpRp M 31 GpRp O 28 GpRp A 21 
GpRp M 11 GpRp O 7 GpRp A 1 GpRp A 22 
GpRp M 12 GpRp O 8 GpRp A 2 GpRp A 23 
GpRp M 13 GpRp O 9 GpRp A 3 GpRp A 24 
GpRp M 14 GpRp O 10 GpRp A 4 GpRp A 25 
GpRp M 15 GpRp O 11 GpRp A 5 GpRp A 26 
GpRp M 16 GpRp O 12 GpRp A 6 GpRp A 27 
GpRp M 17 GpRp O 14 GpRp A 7 GpRp A 28 
GpRp M 18 GpRp O 15 GpRp A 8 GpRp A 29 
GpRp M 19 GpRp O 16 GpRp A 9 GpRp A 30 
GpRp M 20 GpRp O 17 GpRp A 10 GpRp A 31 
GpRp M 21 GpRp O 18 GpRp A 11 
  
      
  
    
Saccostomys sp  
   
Gp Sp 6 
    
  
    
Mus musculus  
 
   
GR. m 1  
   
GR. m 2  
   
GR. m 3  
   
GR. m 4  
   
GR. m 5   
  
    
  
Parotomys sp 
  
  
GR f 1     
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Jonkershoek, 
Stellenbosch  
 
Fragmented habitatNature 
reserve 
 
 
  
Rhabdomys pumilio 
 
J.Hoek Rp 1 JHRp 20 
 
J.Hoek Rp 2 JHRp 21 
 
J.Hoek Rp 3 JHRp 23 
 
J.Hoek Rp 4 JHRp 24 
 
J.Hoek Rp 5 JHRp 26 
 
J.Hoek Rp 6 JHRp 27 
 
JHRp 1 JHRp 28 
 
JHRp 2 JHRp 29 
 
JHRp 3 JHRp 30 
 
JHRp 4 JHRp *31 
 
JHRp 5 JHRp *32 
 
JHRp 6 JHRp *33 
 
JHRp 7 JHRp *34 
 
JHRp 8 JHRp *35 
 
JHRp 12 JHRp *36 
 
JHRp 17 JHRp *37 
 
JHRp 18 JHRp *38 
 
JHRp 19 JHRp *39 
 
   
Otomys irroratus 
 
VET O. irr 1 
  
VET O. irr 2 
  
   
   
Shrews 
  
J. Hoek Shrew 1 
 
J. Hoek Shrew 2 
 
J. Hoek Shrew 3 
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Laingsburg   
Old sheep 
farm   
   
Rhabdomys pumilio 
 
LBRp 1   
LBRp 2   
LBRp 3   
LBRp 4   
LBRp 5   
LBRp 6   
LBRp 7   
LBRp 8   
LBRp 9   
LBRp 10   
LBRp 11   
LBRp 12   
LBRp 13   
LBRp 14   
LBRp 15   
LBRp 17   
LBRp 18   
LBRp 20   
LBRp 22   
LBRp 23   
LBRp 24   
   
Aethomys 
sp.  
 
Ae LB 1  
Ae LB 2  
  
Otomys unisulcatus 
Ou LB 1  
Ou LB 2  
Ou LB 3  
  
shrew  
shrew LB 1  
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Loeriesfontein 
 
farm 
 
 
 
Rhabdomys pumilio 
LfRp 1 
 
LfRp 2 
 
LfRp 3 
 
LfRp 4 
 
LfRp 5 
 
LfRp 6 
 
LfRp 7 
 
LfRp 8 
 
LfRp 9 
 
LfRp 10 
 
LfRp 11 
 
LfRp 12 
 
LfRp 14 
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Middelvlei, Stellenbosch 
 
Fragmented habitat , 
farming 
 
   
Rhabdomys pumilio 
 
MvRp 1 
  
MvRp 2 
  
MvRp 3 
  
MvRp 4 
  
MvRp 5 
  
MvRp 6 
  
MvRp 7 
  
MvRp 8 
  
MvRp 9 
  
MvRp 10 
  
MvRp 11 
  
MvRp 12 
  
MvRp 13 
  
MvRp 14 
  
MvRp 15 
  
MvRp 16 
  
MvRp 17 
  
MvRp 18 
  
MvRp 19 
  
MvRp 20 
  
MvRp 21 
  
MvRp 22 
  
MvRp 23 
  
MvRp 24 
  
MvRp 25 
  
MvRp 26 
  
MvRp 28 
  
MvRp 29 
  
MvRp 30 
  
MvRp 31 
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Mulderbosch, 
Stellenbosch 
        
fragmented habitat, 
farming 
     
   
     
Rhabdomys pumilio 
  
shrew  
  
MBA Rp 1 MB Rp 7 MBM Rp 6  MB shrew 1 
MBA Rp 2 MB Rp 8 MBM Rp 7   
 
MBA Rp 3 MB Rp 9 MBM Rp 8   
 
MBA Rp 4 MB Rp 10 MBM Rp 9   
 
MBA Rp 5 MB Rp 11 MBM Rp 10 
 
 
 
MBA Rp 6 MB Rp 12 MBM Rp 11  
   
MBA Rp 7 MB Rp 13 MBM Rp 12   
  
MBA Rp 8 MB Rp 14 MBM Rp 13 
 
Otomys 
unisulcatus 
  
MBA Rp 9 MB Rp 15 MBM Rp 14 
 
MB O.irr 1 
  
MBA Rp 10 MB Rp 16 MBM Rp 15 
 
MB O.irr 2 
  
MBA Rp 11 MB Rp 17 MBM Rp 16 
 
MB O.irr 3 
  
MBA Rp 12 MB Rp 18 MBM Rp 17 
 
MB O.irr 4 
  
MBA Rp 13 MB Rp 19 MBM Rp 18 
    
MBA Rp 14 MB Rp 20 MBM Rp 19 
    
MBA Rp 15 MB Rp 21 MBM Rp 20  
   
MBA Rp 16 MB Rp 22 MBM Rp 21 
    
MBA Rp 17 MB Rp 23 MBM Rp 22 
    
MBA Rp 18 MB Rp 24 MBM Rp 23 
    
MBA Rp 19 MB Rp 25 MBM Rp 24 
    
MBA Rp 20 MB Rp 26 MBM Rp 25 
    
MBA Rp 22 MB Rp 27 MBM Rp 26 
    
MBA Rp 25 MB Rp 28 MBM Rp 27 
    
MBA Rp 26 MB Rp 29 MBM Rp 28 
    
MBA Rp 27 MB Rp 30 MBM Rp 29 
    
MBA Rp 29 MB Rp 31 MBM Rp 24 
    
MBA Rp 30 MB Rp 32 MBM Rp 25 
    
MB Rp 1 MB Rp 33 MBM Rp 26 
    
MB Rp 2 MBM Rp 1 MBM Rp 27 
    
MB Rp 3 MBM Rp 2 MBM Rp 28 
    
MB Rp 4 MBM Rp 3 MBM Rp 29 
    
MB Rp 5 MBM Rp 4 MBM Rp 30 
    
MB Rp 6 MBM Rp 5 MBM Rp 31 
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Riverlands 
 
  
Shrew 
 
Riverlands shrew 1 
 
 
Stellenbosch 
 
urban 
 
 
 
Rattus rattus 
 
RAT 1 
 
RAT 2 
 
RAT 3 
 
RAT 4 
 
RAT 5 
 
RAT 6 
 
RAT 7 
 
RAT 8 
 
RAT 9 
 
RAT 10 
 
RAT 11 
 
RAT 12 
 
RAT 13 
 
 
 
 
 
 
 
 
 
  
90 
 
Sutherland  
sheep farm  
  
Rhabdomys pumilio 
SlRp 1  
SlRp 2  
SlRp 3  
SlRp 4  
SlRp 5  
SlRp 6  
SlRp 7  
SlRp 8  
SlRp 9  
SlRp 10  
SlRp 11  
SlRp 12  
SlRp 13  
  
Aethomys 
sp.  
 
AeSl 1  
AeSl 2  
AeSl 3  
AeSl 4  
  
Gerbilluris paeba  
GpSl 1  
GpSl 2  
GpSl 3  
GpSl 4  
GpSl 5  
GpSl 6  
GpSl 7  
GpSl 8  
GpSl 9  
  
Otomys unisulcatus 
OuSl 1  
OuSl 2  
OuSl 3  
  
Shrew  
Shrew Sl 1  
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Vergelegen 
 
Wine farm 
 
 
 
Rhabdomys pumilio 
Vg/Vo Rp 1 
 
Vg/Vo Rp 2 
 
Vg/Vo Rp 3 
 
Vg/Vo Rp 4 
 
Vg/Vo Rp 5 
 
Vg/Vo Rp 6 
 
Vg/Vo Rp 7 
 
Vg/Vo Rp 8 
 
Vg/Vo Rp 9 
 
Vg/Vo Rp 10 
 
Vg/Vo Rp 
10# 
 
Vg/Vo Rp 12 
 
Vg/Vo Rp 13 
 
Vg/Vo Rp 14 
 
Vg/Vo Rp 15 
 
Vg/Vo Rp 
17# 
 
Vg/Vo Rp 17 
 
Vg/Vo Rp 18 
 
Vg/Vo Rp 20 
 
Vg Rp 21 
 
Vg Rp 22 
 
Vg Rp 23 
 
Vg Rp 24 
 
 
 
 
Voelvleidam 
 
Nature reserve 
 
 
 
Rhabdomys pumilio 
VdRp 24 
 
VdRp 26 
 
VdRp 27 
 
VdRp 30 
 
 
 
 
 
 
92 
 
Waterval farm 
farm 
 
 
Rhabdomys 
pumilio 
  
WfRp 1 
  
WfRp 2 
  
WfRp 3 
 
WfRp 4 
  
WfRp 5 
  
WfRp 6 
  
WfRp 7 
  
WfRp 8 
  
WfRp 9 
  
WfRp 10 
  
WfRp 11 
  
WfRp 12 
  
WfRp 13 
  
WfRp 15 
  
WfRp 16 
  
WfRp 17 
  
WfRp 18 
  
WfRp 19 
  
WfRp 20 
  
WfRp 21 
  
WfRp 22 
  
WfRp 23 
  
WfRp 24 
  
WfRp 25 
  
WfRp 26 
  
 
  
 
  
 
  
 
Keetmanshoop (Namibia) 
  
Shrew  
keetmans shrew 1 
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Addendum D 
Convenience sero-survey specimens 
 
A. List of sera from female patients 
 
 
Specimen number Age Sex Specimen number Age Sex
HAN-5 37 F HAN-77 62 F
HAN-6 75 F HAN-78 - F
HAN-11 53 F HAN-79 31 F
HAN-13 83 F HAN-80 54 F
HAN-14 3 F HAN-81 37 F
HAN-15 74 F HAN-82 43 F
HAN-16 68 F HAN-84 54 F
HAN-17 1 F HAN-87 34 F
HAN-18 67 F HAN-88 45 F
HAN-19 16 F HAN-89 48 F
HAN-21 32 F HAN-93 28 F
HAN-23 27 F HAN-97 19 F
HAN-24 72 F HAN-98 46 F
HAN-26 47 F HAN-99 50 F
HAN-27 31 F HAN-100 45 F
HAN-29 37 F HAN-106 15 F
HAN-30 31 F HAN-108 32 F
HAN-32 80 F HAN-109 30 F
HAN-33 52 F HAN-112 43 F
HAN-35 66 F HAN-113 51 F
HAN-36 59 F HAN-114 32 F
HAN-37 41 F HAN-115 28 F
HAN-39 47 F HAN-117 72 F
HAN-40 37 F HAN-118 24 F
HAN-41 16 F HAN-119 38 F
HAN-42 20 F HAN-120 88 F
HAN-44 86 F HAN-121 38 F
HAN-48 86 F HAN-124 24 F
HAN-49 76 F HAN-125 76 F
HAN-50 54 F HAN-127 67 F
HAN-51 59 F HAN-128 45 F
HAN-52 27 F HAN-129 19 F
HAN-54 48 F HAN-131 29 F
HAN-55 30 F HAN-132 34 F
HAN-56 60 F HAN-133 69 F
HAN-57 - F HAN-137 74 F
HAN-58 83 F HAN-138 74 F
HAN-59 65 F HAN-139 38 F
HAN-61 42 F HAN-141 63 F
HAN-62 52 F HAN-142 33 F
HAN-63 39 F HAN-145 46 F
HAN-64 83 F HAN-146 37 F
HAN-65 56 F HAN-147 37 F
HAN-67 27 F HAN-148 80 F
HAN-68 51 F HAN-152 29 F
HAN-70 59 F HAN-154 18 F
HAN-72 27 F HAN-156 10 F
HAN-73 26 F HAN-157 49 F
HAN-74 46 F HAN-159 29 F
HAN-76 70 F
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List of sera from male patients  
 
 
Specimen number Age Sex Specimen number Age Sex
HAN-1 68 M HAN-94 60 M
HAN-2 48 M HAN-95 22 M
HAN-3 31 M HAN-96 61 M
HAN-4 41 M HAN-101 45 M
HAN-7 50 M HAN-102 28 M
HAN-8 21 M HAN-103 58 M
HAN-9 40 M HAN-104 46 M
HAN-10 55 M HAN-105 20 M
HAN-12 61 M HAN-107 34 M
HAN-20 45 M HAN-110 59 M
HAN-22 56 M HAN-111 46 M
HAN-25 62 M HAN-116 58 M
HAN-28 73 M HAN-122 28 M
HAN-31 33 M HAN-123 62 M
HAN-34 51 M HAN-126 28 M
HAN-38 54 M HAN-130 16 M
HAN-43 15 M HAN-134 24 M
HAN-45 82 M HAN-135 59 M
HAN-46 57 M HAN-136 - M
HAN-47 13 M HAN-140 41 M
HAN-53 42 M HAN-143 59 M
HAN-60 47 M HAN-144 61 M
HAN-66 52 M HAN-149 49 M
HAN-71 68 M HAN-150 46 M
HAN-75 81 M HAN-151 68 M
HAN-83 51 M HAN-153 40 M
HAN-85 20 M HAN-155 13 M
HAN-86 65 M HAN-158 16 M
HAN-90 24 M HAN-160 34 M
HAN-91 50 M HAN-161 71 M
HAN-92 70 M
